

# CITATION REPORT

List of articles citing

Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease

DOI: 10.1002/hep.22848  
Hepatology, 2009, 49, 1877-87.

**Source:** <https://exaly.com/paper-pdf/46061105/citation-report.pdf>

**Version:** 2024-04-29

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1028	The gut-liver axis in nonalcoholic fatty liver disease: Another pathway to insulin resistance?. <i>Hepatology</i> , <b>2009</b> , 49, 1790-2	11.2	27
1027	The immunopathogenesis of alcoholic and nonalcoholic steatohepatitis: two triggers for one disease?. <b>2009</b> , 31, 359-69		72
1026	Non-alcoholic fatty liver disease from pathogenesis to management: an update. <b>2010</b> , 11, 430-45		128
1025	Recent advances in nonalcoholic fatty liver disease. <b>2010</b> , 26, 202-8		119
1024	Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: mechanisms and implications for metabolic disorders. <b>2010</b> , 21, 76-83		126
1023	Current Opinion in Lipidology. Current world literature. <b>2010</b> , 21, 84-8		
1022	Zonula Occludens-1 alterations and enhanced intestinal permeability in methotrexate-treated rats. <b>2010</b> , 66, 1031-8		53
1021	Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. <i>Hepatology</i> , <b>2010</b> , 52, 1836-46	11.2	1423
1020	Nonalcoholic fatty liver disease. <b>2010</b> , 24, 695-708		140
1019	Elevated endotoxin levels in non-alcoholic fatty liver disease. <b>2010</b> , 7, 15		251
1018	Hepatic manifestations of celiac disease. <b>2010</b> , 3, 33-9		18
1017	Roles of liver innate immune cells in nonalcoholic fatty liver disease. <b>2010</b> , 16, 4652-60		67
1016	Gut-liver axis and sensing microbes. <b>2010</b> , 28, 737-44		132
1015	Intestinal permeability in cirrhotic patients with and without spontaneous bacterial peritonitis: is the ring closed?. <b>2010</b> , 105, 323-7		79
1014	Contribution of gut bacteria to liver pathobiology. <b>2010</b> , 2010,		90
1013	Pathophysiological similarities and synergisms in alcoholic and non-alcoholic steatohepatitis. <b>2010</b> , 28, 783-91		11
1012	Clinical physiology of NAFLD: a critical overview of pathogenesis and treatment. <b>2010</b> , 5, 403-423		16

1011	Probiotics and gut health: a special focus on liver diseases. <b>2010</b> , 16, 403-10	85
1010	The role of the gut microbiota in nonalcoholic fatty liver disease. <b>2010</b> , 7, 691-701	341
1009	Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. <b>2010</b> , 31, 817-44	315
1008	Pathogenesis of non-alcoholic fatty liver disease. <b>2010</b> , 103, 71-83	462
1007	Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. <b>2010</b> , 139, 323-34.e7	528
1006	Protective effects of <i>Lactobacillus paracasei</i> F19 in a rat model of oxidative and metabolic hepatic injury. <b>2010</b> , 299, G669-76	68
1005	Enfermedad del hígado graso no alcohólico y riesgo cardiovascular. <b>2010</b> , 22, 259-271	
1004	Small intestinal bacterial overgrowth. <b>2010</b> , 24, 943-59, viii-ix	72
1003	Nonalcoholic Fatty Liver Disease. <b>2011</b> , 868-907	1
1002	Role of the inducible nitric oxide synthase in the onset of fructose-induced steatosis in mice. <b>2011</b> , 14, 2121-35	67
1001	First European Young Hepatologist Workshop: topics and advances. <b>2011</b> , 35 Suppl 1, S1-2	
1000	Liver fibrogenesis and metabolic factors. <b>2011</b> , 35 Suppl 1, S10-20	25
999	Intestinal permeability is associated with visceral adiposity in healthy women. <b>2011</b> , 19, 2280-2	95
998	Gut microbiota and probiotics in chronic liver diseases. <b>2011</b> , 43, 431-8	115
997	Inflammation in nonalcoholic steatohepatitis. <b>2011</b> , 5, 189-200	60
996	Gluten-sensitive hypertransaminasemia in celiac disease: an infrequent and often subclinical finding. <b>2011</b> , 106, 1689-96	31
995	Clinicopathological features of non-alcoholic fatty liver disease. <b>2011</b> , 41, 911-20	20
994	DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. <b>2011</b> , 55, 1391-9	186

993	Contribution of the intestinal microbiota to human health: from birth to 100 years of age. <b>2013</b> , 358, 323-46	44
992	Diet, commensals and the intestine as sources of pathogen-associated molecular patterns in atherosclerosis, type 2 diabetes and non-alcoholic fatty liver disease. <b>2011</b> , 216, 1-6	57
991	Non-Alcoholic Fatty Liver Disease and Nutrition. <b>2011</b> , 546-567	6
990	The unfolding web of innate immune dysregulation in alcoholic liver injury. <b>2011</b> , 35, 782-6	59
989	A new model of interactive effects of alcohol and high-fat diet on hepatic fibrosis. <b>2011</b> , 35, 1361-7	61
988	Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes. <b>2011</b> , 62, 361-80	431
987	Interaction between obesity and the gut microbiota: relevance in nutrition. <b>2011</b> , 31, 15-31	308
986	Gut microbiota and its pathophysiology in disease paradigms. <b>2011</b> , 29, 518-24	41
985	Abnormal small intestinal permeability in patients with idiopathic malabsorption in tropics (tropical sprue) does not change even after successful treatment. <b>2011</b> , 56, 161-9	14
984	Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. <i>Hepatology</i> , <b>2011</b> , 54, 133-44	11.2 424
983	Suppression of inducible nitric oxide synthase expression and amelioration of lipopolysaccharide-induced liver injury by polyphenolic compounds in Eucalyptus globulus leaf extract. <b>2011</b> , 125, 442-446	14
982	Hepatobiliary disorders in celiac disease: an update. <b>2011</b> , 2011, 438184	14
981	Endoplasmic reticulum stress and the unfolded protein response in nonalcoholic fatty liver disease. <b>2011</b> , 15, 505-21	75
980	Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. <b>2011</b> , 52, 740-3	217
979	Gut microbiota is a key modulator of insulin resistance in TLR 2 knockout mice. <b>2011</b> , 9, e1001212	202
978	Organelle dysfunction in hepatitis C virus-associated steatosis: anything to learn from nonalcoholic steatohepatitis?. <b>2011</b> , 5, 265-77	1
977	The intestinal microbiome and the leaky gut as therapeutic targets in alcoholic liver disease. <b>2012</b> , 3, 402	64
976	The Intestinal Microbiota and Liver Disease. <b>2012</b> , 1, 9-14	30

975	Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. <b>2012</b> , 3, 279-88	527
974	Metformin protects against the development of fructose-induced steatosis in mice: role of the intestinal barrier function. <b>2012</b> , 92, 1020-32	114
973	Microbial translocation in chronic liver diseases. <b>2012</b> , 2012, 694629	67
972	The gut barrier: new acquisitions and therapeutic approaches. <b>2012</b> , 46 Suppl, S12-7	132
971	Obesity-independent association of human adenovirus Ad37 seropositivity with nonalcoholic fatty liver disease. <b>2012</b> , 46, e46-54	18
970	Increased intestinal permeability and Parkinson disease patients: chicken or egg?. <b>2012</b> , 39, 185-8	46
969	Toll-like receptors 1-9 are elevated in livers with fructose-induced hepatic steatosis. <b>2012</b> , 107, 1727-38	96
968	Human serum proteome analysis: new source of markers in metabolic disorders. <b>2012</b> , 6, 759-73	19
967	NASH and atherosclerosis are two aspects of a shared disease: central role for macrophages. <b>2012</b> , 220, 287-93	66
966	A myriad of pathways to NASH. <b>2012</b> , 16, 525-48	33
965	Gut-liver axis: the impact of gut microbiota on non alcoholic fatty liver disease. <b>2012</b> , 22, 471-6	270
964	The potential role of prebiotic fibre for treatment and management of non-alcoholic fatty liver disease and associated obesity and insulin resistance. <b>2012</b> , 32, 701-11	135
963	Endoplasmic reticulum stress in nonalcoholic fatty liver disease. <b>2012</b> , 32, 17-33	168
962	Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease. <b>2012</b> , 56, 1283-92	219
961	[Nonalcoholic fatty liver disease]. <b>2012</b> , 41, 169-89	4
960	Liver repercussions of defective gut surveillance. <i>Hepatology</i> , <b>2012</b> , 56, 1174-7	11.2 2
959	Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. <b>2012</b> , 16, 44-54	232
958	Inulin-enriched pasta improves intestinal permeability and modifies the circulating levels of zonulin and glucagon-like peptide 2 in healthy young volunteers. <b>2012</b> , 32, 940-6	75

957	Probiotics in the treatment of the liver diseases. <b>2012</b> , 31, 14-23	39
956	Causative role of gut microbiota in non-alcoholic fatty liver disease pathogenesis. <b>2012</b> , 2, 132	36
955	Gut microbiota and nonalcoholic fatty liver disease. <b>2012</b> , 11, 440-449	116
954	NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications. <b>2012</b> , 6, 149-71	278
953	Leaky gut and the liver: a role for bacterial translocation in nonalcoholic steatohepatitis. <b>2012</b> , 18, 2609-18	132
952	Alleviation of insulin resistance and liver damage by oral administration of Imm124-E is mediated by increased Tregs and associated with increased serum GLP-1 and adiponectin: results of a phase I/II clinical trial in NASH. <b>2012</b> , 5, 141-50	54
951	Female mice are more susceptible to nonalcoholic fatty liver disease: sex-specific regulation of the hepatic AMP-activated protein kinase-plasminogen activator inhibitor 1 cascade, but not the hepatic endotoxin response. <b>2012</b> , 18, 1346-55	60
950	Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. <b>2012</b> , 590, 447-58	270
949	Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease (NAFLD). <b>2012</b> , 57, 1932-41	187
948	Comparison of the gut microbe profiles and numbers between patients with liver cirrhosis and healthy individuals. <b>2012</b> , 65, 7-13	54
947	Oral administration of immunoglobulin G-enhanced colostrum alleviates insulin resistance and liver injury and is associated with alterations in natural killer T cells. <b>2012</b> , 167, 252-60	53
946	The epidemiology, pathogenesis and histopathology of fatty liver disease. <b>2012</b> , 61, 141-52	125
945	Adenovirus-36 seropositivity enhances effects of nutritional intervention on obesity, bright liver, and insulin resistance. <b>2012</b> , 57, 535-44	44
944	The intestinal microbiota in chronic liver disease. <b>2013</b> , 117, 73-97	41
943	Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. <b>2013</b> , 28 Suppl 1, 68-76	170
942	Maturation defective myeloid dendritic cells in nonalcoholic fatty liver disease patients release inflammatory cytokines in response to endotoxin. <b>2013</b> , 7, 562-9	5
941	A moderate weight reduction through dietary intervention decreases hepatic fat content in patients with non-alcoholic fatty liver disease (NAFLD): a pilot study. <b>2013</b> , 52, 527-35	58
940	Toll-like receptors in alcoholic liver disease, non-alcoholic steatohepatitis and carcinogenesis. <b>2013</b> , 28 Suppl 1, 38-42	185

939	Non-alcoholic fatty liver disease and cardiovascular risk. <b>2013</b> , 167, 1109-17		64
938	Gut microbiota and non-alcoholic fatty liver disease: new insights. <b>2013</b> , 19, 338-48		157
937	Nonalcoholic fatty liver disease: for better or worse, blame the gut microbiota?. <b>2013</b> , 37, 787-93		20
936	Clinical consequences of diet-induced dysbiosis. <b>2013</b> , 63 Suppl 2, 28-40		81
935	Role of the intestinal microbiome in liver disease. <b>2013</b> , 46, 66-73		137
934	Immune and inflammatory pathways in NASH. <b>2013</b> , 7 Suppl 2, 771-81		121
933	Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. <i>Hepatology</i> , <b>2013</b> , 57, 601-9	11.2	904
932	Therapeutic potential of fecal microbiota transplantation. <b>2013</b> , 145, 946-53		395
931	Oat $\beta$ -glucan inhibits lipopolysaccharide-induced nonalcoholic steatohepatitis in mice. <b>2013</b> , 4, 1360-8		13
930	Metabolic endotoxemia: a molecular link between obesity and cardiovascular risk. <b>2013</b> , 51, R51-64		125
929	Altered expression and function of hepatic natural killer T cells in obese and diabetic KK-A(y) mice. <b>2013</b> , 43, 276-88		7
928	Role of gut microbiota in liver diseases. <b>2013</b> , 43, 139-46		53
927	Prevalence of coeliac disease in patients with non-alcoholic fatty liver disease. <b>2013</b> , 14, 113-5		13
926	<i>Lactobacillus casei</i> Shirota protects from fructose-induced liver steatosis: a mouse model. <b>2013</b> , 24, 531-8		86
925	Association between non-alcoholic fatty liver disease, insulin resistance and <i>Helicobacter pylori</i> . <b>2013</b> , 81, 913-5		15
924	A pathogenetic link between non-alcoholic fatty liver disease and celiac disease. <b>2013</b> , 43, 65-7		20
923	Intestinal microbiota in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , <b>2013</b> , 58, 120-7	11.2	461
922	Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. <b>2013</b> , 10, 330-44		1022

921	Genetically obese mice do not show increased gut permeability or faecal bile acid hydrophobicity. <b>2013</b> , 110, 1157-64	22
920	Innate immune receptors: key regulators of metabolic disease progression. <b>2013</b> , 17, 873-882	119
919	Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: an input for novel therapies. <b>2013</b> , 45, 543-51	60
918	Intestinal epithelial barrier function in liver cirrhosis: an extensive review of the literature. <b>2013</b> , 33, 1457-69	73
917	Symbiotic formulation in experimentally induced liver fibrosis in rats: intestinal microbiota as a key point to treat liver damage?. <b>2013</b> , 33, 687-97	23
916	A novel mechanism for gut barrier dysfunction by dietary fat: epithelial disruption by hydrophobic bile acids. <b>2013</b> , 304, G227-34	132
915	Increasing whole grain intake as part of prevention and treatment of nonalcoholic Fatty liver disease. <b>2013</b> , 2013, 585876	34
914	The role of celiac disease in severity of liver disorders and effect of a gluten free diet on diseases improvement. <b>2013</b> , 13, e11893	5
913	Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH). <b>2013</b> , 14, 20704-28	234
912	Microbiota and gut-liver axis: their influences on obesity and obesity-related liver disease. <b>2013</b> , 56, 461-8	134
911	Lactobacillus casei strain Shirota protects against nonalcoholic steatohepatitis development in a rodent model. <b>2013</b> , 305, G911-8	66
910	Celiac disease and autoimmune-associated conditions. <b>2013</b> , 2013, 127589	90
909	Adiponectin, bile acids, and burnt-out nonalcoholic steatohepatitis: new light on an old paradox. <i>Hepatology</i> , <b>2013</b> , 57, 2106-9	11.2 9
908	Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. <b>2013</b> , 19, 5219-38	148
907	What does irritable bowel syndrome share with non-alcoholic fatty liver disease?. <b>2013</b> , 19, 5402-20	15
906	Gastrointestinal complications of diabetes mellitus. <b>2013</b> , 4, 51-63	103
905	Pathophysiology of NASH: perspectives for a targeted treatment. <b>2013</b> , 19, 5250-69	110
904	Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. <b>2013</b> , 19, 6911-8	227



903	Butyrate-producing probiotics reduce nonalcoholic fatty liver disease progression in rats: new insight into the probiotics for the gut-liver axis. <b>2013</b> , 8, e63388	216
902	Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis--a longitudinal study. <b>2013</b> , 8, e62885	205
901	Gut microbiota and clinical disease: obesity and nonalcoholic Fatty liver disease. <b>2013</b> , 16, 22-7	35
900	Dietary anthocyanins as nutritional therapy for nonalcoholic fatty liver disease. <b>2013</b> , 2013, 145421	81
899	Probiotic as a novel treatment strategy against liver disease. <b>2013</b> , 13, e7521	45
898	Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. <b>2013</b> , 12, 256-262	187
897	Probiotics in non-alcoholic fatty liver disease: which and when. <b>2013</b> , 12, 357-363	27
896	The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease. <b>2014</b> , 6, 5583-99	65
895	Increased circulating zonulin in children with biopsy-proven nonalcoholic fatty liver disease. <b>2014</b> , 20, 17107-14	38
894	Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease. <b>2015</b> , 7, 204-12	50
893	Surgical treatment of nonalcoholic fatty liver disease in severely obese patients. <b>2014</b> , 6, 103-12	8
892	Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease. <b>2014</b> , 20, 15518-31	111
891	Non-alcoholic fatty liver disease: what the clinician needs to know. <b>2014</b> , 20, 12956-80	117
890	Obesity, fatty liver disease and intestinal microbiota. <b>2014</b> , 20, 16452-63	109
889	Le microbiote et les stàtopathies mtaboliques. <b>2014</b> , 198, 1641-1652	
888	Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH). <b>2014</b> , 15, 7352-79	87
887	Non-alcoholic fatty liver disease in patients with diabetes mellitus. <b>2014</b> , 9, 503-514	
886	Current pharmacotherapy for treating pediatric nonalcoholic fatty liver disease. <b>2014</b> , 15, 2501-11	6

885	Endotoxemia unrequired in the pathogenesis of pediatric nonalcoholic steatohepatitis. <b>2014</b> , 29, 1292-8	51
884	Increased intestinal permeability to oral chromium (51 Cr) -EDTA in human Type 2 diabetes. <b>2014</b> , 31, 559-63	69
883	A comparison of cardiovascular risk indices in patients with polycystic ovary syndrome with and without coexisting nonalcoholic fatty liver disease. <b>2014</b> , 80, 843-9	16
882	Paradoxical impact of the remnant pancreatic volume and infectious complications on the development of nonalcoholic fatty liver disease after pancreaticoduodenectomy. <b>2014</b> , 21, 562-72	27
881	Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. <b>2014</b> , 39, 1276-85	269
880	The liver may act as a firewall mediating mutualism between the host and its gut commensal microbiota. <b>2014</b> , 6, 237ra66	257
879	Interleukin-10 and Kupffer cells protect steatotic mice livers from ischemia-reperfusion injury. <b>2014</b> , 25, 69-76	24
878	Nutrition, nonalcoholic fatty liver disease and the microbiome: recent progress in the field. <b>2014</b> , 25, 61-6	29
877	Gut microbiota and metabolic syndrome. <b>2014</b> , 20, 16079-94	282
876	Modulation of immunity and inflammatory gene expression in the gut, in inflammatory diseases of the gut and in the liver by probiotics. <b>2014</b> , 20, 15632-49	139
875	Fructose induced endotoxemia in pediatric nonalcoholic Fatty liver disease. <b>2014</b> , 2014, 560620	60
874	4Ps medicine of the fatty liver: the research model of predictive, preventive, personalized and participatory medicine-recommendations for facing obesity, fatty liver and fibrosis epidemics. <b>2014</b> , 5, 21	24
873	Gut-adipose tissue axis in hepatic fat accumulation in humans. <b>2014</b> , 61, 132-8	36
872	Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity. <b>2014</b> , 46, 556-60	115
871	Obesity and NAFLD: the role of bacteria and microbiota. <b>2014</b> , 18, 59-71	72
870	A case-control study on the effect of metabolic gene polymorphisms, nutrition, and their interaction on the risk of non-alcoholic fatty liver disease. <b>2014</b> , 9, 383	29
869	Microbiota and nonalcoholic steatohepatitis. <b>2014</b> , 36, 115-32	29
868	Serum lipocalin-2, cathepsin S and chemerin levels and nonalcoholic fatty liver disease. <b>2014</b> , 41, 1317-23	19

867	Mechanisms of Liver Injury in Non-Alcoholic Steatohepatitis. <b>2014</b> , 13, 119-129	26
866	Interactions between the intestinal microbiome and liver diseases. <b>2014</b> , 146, 1513-24	596
865	Pediatric non-alcoholic fatty liver disease: recent advances. <b>2014</b> , 38, 419-22	14
864	Inflammasomes and metabolic disease. <b>2014</b> , 76, 57-78	91
863	Gut microbiome and metabolic diseases. <b>2014</b> , 36, 103-14	98
862	Functional and metabolic disorders in celiac disease: new implications for nutritional treatment. <b>2014</b> , 17, 1159-64	14
861	Emodin attenuates systemic and liver inflammation in hyperlipidemic mice administrated with lipopolysaccharides. <b>2014</b> , 239, 1025-1035	31
860	Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. <b>2014</b> , 99, 535-42	226
859	Asymptomatic gastric bacterial overgrowth after bariatric surgery: are long-term metabolic consequences possible?. <b>2014</b> , 24, 1856-61	16
858	NAFLD and Cardiovascular Disease: Can the Real Association Be Determined?. <b>2014</b> , 13, 130-141	4
857	NASH and the Cross-Talk Between the Gut and Liver. <b>2014</b> , 2, 211-217	1
856	Review article: the management of paediatric nonalcoholic fatty liver disease. <b>2014</b> , 40, 1155-70	33
855	When specific gut microbes reveal a possible link between hepatic steatosis and adipose tissue. <b>2014</b> , 61, 5-6	11
854	Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice. <i>Hepatology</i> , <b>2014</b> , 59, 1738-49	11.2 188
853	Activation of farnesoid X receptor (FXR) protects against fructose-induced liver steatosis via inflammatory inhibition and ADRP reduction. <b>2014</b> , 450, 117-23	31
852	Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease. <b>2014</b> , 20, 16841-57	31
851	Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease. <b>2014</b> , 20, 7381-91	209
850	Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. <b>2014</b> , 20, 18070-91	208

849	Supplementation of sodium butyrate protects mice from the development of non-alcoholic steatohepatitis (NASH). <b>2015</b> , 114, 1745-55	70
848	Microbiome-Immune Interactions and Liver Disease. <b>2015</b> , 5, 83-85	1
847	Age-related sensitivity to endotoxin-induced liver inflammation: Implication of inflammasome/IL-1 $\beta$ for steatohepatitis. <b>2015</b> , 14, 524-33	24
846	Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease. <b>2015</b> , 42, 1051-63	122
845	Adaptation of the human aryl hydrocarbon receptor to sense microbiota-derived indoles. <b>2015</b> , 5, 12689	183
844	[Gut Microbiota and Internal Diseases: Update Information. Topics: III. NASH/NAFLD and gut microbiota]. <b>2015</b> , 104, 48-56	
843	The Gut Microbiota, Intestinal Permeability, Bacterial Translocation, and Nonalcoholic Fatty Liver Disease: What Comes First?. <b>2015</b> , 1, 129-130	2
842	The gut microbiome as a target for regulatory T cell-based immunotherapy: induction of regulatory lymphocytes by oral administration of anti-LPS enriched colostrum alleviates immune mediated colitis. <b>2015</b> , 15, 154	25
841	Probiotics in Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, and Cirrhosis. <b>2015</b> , 49 Suppl 1, S28-32	12
840	Gluten-free snacks using plantain-chickpea and maize blend: chemical composition, starch digestibility, and predicted glycemic index. <b>2015</b> , 80, C961-6	38
839	Bacterial endotoxin and non-alcoholic fatty liver disease in the general population: a prospective cohort study. <b>2015</b> , 42, 731-40	46
838	Non-alcoholic fatty liver disease as a consequence of autonomic imbalance and circadian desynchronization. <b>2015</b> , 16, 871-82	15
837	Effect of microbial cell preparation on renal profile and liver function among type 2 diabetics: a randomized controlled trial. <b>2015</b> , 15, 433	22
836	Fructose and liver function--is this behind nonalcoholic liver disease?. <b>2015</b> , 18, 490-5	19
835	Gut dysbiosis in acute-on-chronic liver failure and its predictive value for mortality. <b>2015</b> , 30, 1429-37	93
834	CX3CR1 is a gatekeeper for intestinal barrier integrity in mice: Limiting steatohepatitis by maintaining intestinal homeostasis. <i>Hepatology</i> , <b>2015</b> , 62, 1405-16	11.2 61
833	Gut Microbiota and Energy Expenditure in Health and Obesity. <b>2015</b> , 49 Suppl 1, S13-9	13
832	Obesity is independently associated with infection in hospitalised patients with end-stage liver disease. <b>2015</b> , 42, 1271-80	15

831	Role of gut barrier function in the pathogenesis of nonalcoholic Fatty liver disease. <b>2015</b> , 2015, 287348	32
830	Liver involvement in pediatric celiac disease. <b>2015</b> , 21, 5813-22	36
829	Gut microbiota and liver diseases. <b>2015</b> , 21, 1691-702	94
828	Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease. <b>2015</b> , 7, 559-65	29
827	Relevant Aspects of Nutritional and Dietary Interventions in Non-Alcoholic Fatty Liver Disease. <b>2015</b> , 16, 25168-98	76
826	Gut Microbiota and Host Reaction in Liver Diseases. <b>2015</b> , 3, 759-91	31
825	Nutritional Keys for Intestinal Barrier Modulation. <b>2015</b> , 6, 612	115
824	Vitamin D: a new player in non-alcoholic fatty liver disease?. <b>2015</b> , 21, 1718-27	89
823	MicroRNA-155 Deficiency Attenuates Liver Steatosis and Fibrosis without Reducing Inflammation in a Mouse Model of Steatohepatitis. <b>2015</b> , 10, e0129251	61
822	Co-Administration of Cholesterol-Lowering Probiotics and Anthraquinone from Cassia obtusifolia L. Ameliorate Non-Alcoholic Fatty Liver. <b>2015</b> , 10, e0138078	37
821	Gut Microbiota: Association with NAFLD and Metabolic Disturbances. <b>2015</b> , 2015, 979515	44
820	Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis. <b>2015</b> , 2015, 460190	89
819	Histologic and Metabolic Derangement in High-Fat, High-Fructose, and Combination Diet Animal Models. <b>2015</b> , 2015, 306326	19
818	Treatment of nonalcoholic steatohepatitis in adults: present and future. <b>2015</b> , 2015, 732870	19
817	LPS-induced TNF- $\alpha$ factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease. <b>2015</b> , 6, 41434-52	78
816	Influence of gut bacteria on development and progression of non-alcoholic fatty liver disease. <b>2015</b> , 7, 1679-84	19
815	Recent advances in mouse models of obesity- and nonalcoholic steatohepatitis-associated hepatocarcinogenesis. <b>2015</b> , 7, 2110-8	33
814	The gut microbiota and liver disease. <b>2015</b> , 1, 275-284	104

813	Oxidative Stress in Nonalcoholic Fatty Liver Disease. <b>2015</b> , 279-308	1
812	Chronic inflammation aggravates metabolic disorders of hepatic fatty acids in high-fat diet-induced obese mice. <b>2015</b> , 5, 10222	34
811	Ontogeny and polarization of macrophages in inflammation: blood monocytes versus tissue macrophages. <b>2014</b> , 5, 683	151
810	Shared symptoms and putative biological mechanisms in chronic liver disease: implications for biobehavioral research. <b>2015</b> , 17, 222-9	3
809	Gut microbiota and non-alcoholic fatty liver disease. <b>2015</b> , 14, 572-81	45
808	The Role of Integrated Omics in Elucidating the Gut Microbiota Health Potentials. <b>2015</b> , 73-100	2
807	Risk Factors for Polyautoimmunity among Patients with Celiac Disease: A Cross-Sectional Survey. <b>2015</b> , 92, 185-91	17
806	Early life events influence whole-of-life metabolic health via gut microflora and gut permeability. <b>2015</b> , 41, 326-40	72
805	Increased risk of non-alcoholic fatty liver disease after diagnosis of celiac disease. <b>2015</b> , 62, 1405-11	53
804	Role of serum toll-like receptors 2 and 4 in non-alcoholic steatohepatitis and liver fibrosis. <b>2015</b> , 30, 1190-6	28
803	Helicobacter pylori infection might have a potential role in hepatocyte ballooning in nonalcoholic fatty liver disease. <b>2015</b> , 50, 996-1004	41
802	Arginase 2 deficiency results in spontaneous steatohepatitis: a novel link between innate immune activation and hepatic de novo lipogenesis. <b>2015</b> , 62, 412-20	50
801	Interferon- $\gamma$ Mediates Signaling Pathways Uniquely Regulated in Hepatic Stellate Cells and Attenuates the Progression of Hepatic Fibrosis in a Dietary Mouse Model. <b>2015</b> , 35, 464-73	4
800	Pathological implications of cadherin zonation in mouse liver. <b>2015</b> , 72, 2599-612	18
799	Gut permeability, its interaction with gut microflora and effects on metabolic health are mediated by the lymphatics system, liver and bile acid. <b>2015</b> , 10, 1339-53	31
798	Oral Glutamine Supplementation Protects Female Mice from Nonalcoholic Steatohepatitis. <b>2015</b> , 145, 2280-6	20
797	The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis. <b>2015</b> , 5, 147-58	81
796	Physiology and pathophysiology of liver lipid metabolism. <b>2015</b> , 9, 1055-67	50

795	Gut-liver axis, nutrition, and non-alcoholic fatty liver disease. <b>2015</b> , 48, 923-30	165
794	Interactions of Hepatitis B Virus Infection with Nonalcoholic Fatty Liver Disease: Possible Mechanisms and Clinical Impact. <b>2015</b> , 60, 3513-24	29
793	Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis. <b>2015</b> , 63, 1272-84	323
792	Management and diagnosis of fatty liver disease. <b>2015</b> , 9, 671-83	7
791	Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms. <b>2015</b> , 15, 607	74
790	La perméabilité intestinale dans les maladies métaboliques : porosité ou tanchité?. <b>2015</b> , 9, 11-17	1
789	Docosahexaenoic acid and non-alcoholic fatty liver disease in obese children: a novel approach?. <b>2015</b> , 13, 109	3
788	The complex myeloid network of the liver with diverse functional capacity at steady state and in inflammation. <b>2015</b> , 6, 179	49
787	Urinary (1)H-NMR-based metabolic profiling of children with NAFLD undergoing VSL#3 treatment. <b>2015</b> , 39, 1118-25	43
786	New medical treatment strategies for nonalcoholic steatohepatitis. <b>2015</b> , 13, 259-73	2
785	Gut Microbiota and Metabolic Diseases: From Pathogenesis to Therapeutic Perspective. <b>2015</b> , 199-234	5
784	Non-Alcoholic Fatty Liver Disease (NAFLD): The Lipid Disease of the Liver and the Effect of Statins. <b>2015</b> , 149-173	1
783	Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model. <b>2015</b> , 11, 1693-700	57
782	Hepatic Injury in Nonalcoholic Steatohepatitis Contributes to Altered Intestinal Permeability. <b>2015</b> , 1, 222-232	147
781	The gut microbiota of nonalcoholic fatty liver disease: current methods and their interpretation. <b>2015</b> , 9, 406-15	28
780	Clinical and pathophysiological consequences of alterations in the microbiome in cirrhosis. <b>2015</b> , 110, 1399-410; quiz 1411	29
779	Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease. <b>2015</b> , 30, 780-6	27
778	Mechanistic link between nonalcoholic fatty liver disease and cardiometabolic disorders. <b>2015</b> , 201, 408-14	44

777	Hepatic TLR4 signaling in obese NAFLD. <b>2015</b> , 309, G270-8	138
776	Expression of toll-like receptors 1-5 but not TLR 6-10 is elevated in livers of patients with non-alcoholic fatty liver disease. <b>2015</b> , 35, 562-8	36
775	Natural killer T cells play a necessary role in modulating of immune-mediated liver injury by gut microbiota. <b>2014</b> , 4, 7259	45
774	Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. <b>2015</b> , 47, 181-90	430
773	Pediatric small intestine bacterial overgrowth in low-income countries. <b>2015</b> , 21, 6-15	33
772	Irritable Bowel Syndrome May Be Associated with Elevated Alanine Aminotransferase and Metabolic Syndrome. <b>2016</b> , 57, 146-52	16
771	Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article. <b>2016</b> , 22, 7727-34	39
770	Nutritional Status and Gastrointestinal Health in the Elderly. <b>2016</b> , 363-373	1
769	Distinctly altered gut microbiota in the progression of liver disease. <b>2016</b> , 7, 19355-66	130
768	Correlating the Gut Microbiome to Health and Disease. <b>2016</b> , 261-291	4
767	Prophylactic Effect of Lactobacillus pentosus strain S-PT84 on Candida Infection and Gastric Inflammation in a Murine Gastrointestinal Candidiasis Model. <b>2016</b> , 57, E81-E92	2
766	The Immune Landscape in Nonalcoholic Steatohepatitis. <b>2016</b> , 16, 147-58	34
765	Prophylactic Effect of Lactobacillus pentosus strain S-PT84 on Candida Infection and Gastric Inflammation in a Murine Gastrointestinal Candidiasis Model [Errata]. <b>2016</b> , 57, E81-E92	5
764	The Pathogenesis of Nonalcoholic Fatty Liver Disease: Interplay between Diet, Gut Microbiota, and Genetic Background. <b>2016</b> , 2016, 2862173	102
763	A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD. <b>2016</b> , 2016, 7109270	42
762	Nutrition and Physical Activity in Nonalcoholic Fatty Liver Disease. <b>2016</b> , 2016, 4597246	32
761	Tight Junction Disruption Induced by Type 3 Secretion System Effectors Injected by Enteropathogenic and Enterohemorrhagic Escherichia coli. <b>2016</b> , 6, 87	44
760	Diet, Microbiota, Obesity, and NAFLD: A Dangerous Quartet. <b>2016</b> , 17, 481	70



759	The Metabolic Role of Gut Microbiota in the Development of Nonalcoholic Fatty Liver Disease and Cardiovascular Disease. <b>2016</b> , 17,	42
758	Molecular Pathogenesis of NASH. <b>2016</b> , 17,	100
757	The Potential Mechanisms of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease. <b>2016</b> , 21,	30
756	Apple-Derived Pectin Modulates Gut Microbiota, Improves Gut Barrier Function, and Attenuates Metabolic Endotoxemia in Rats with Diet-Induced Obesity. <b>2016</b> , 8, 126	112
755	Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis. <b>2016</b> , 8,	60
754	Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease. <b>2016</b> , 11, e0151829	203
753	Pro-Inflammatory Cytokines but Not Endotoxin-Related Parameters Associate with Disease Severity in Patients with NAFLD. <b>2016</b> , 11, e0166048	40
752	Overexpression of Peroxiredoxin 4 Affects Intestinal Function in a Dietary Mouse Model of Nonalcoholic Fatty Liver Disease. <b>2016</b> , 11, e0152549	26
751	Toll-like receptors in pathophysiology of liver diseases. <b>2016</b> , 8, 1354-1369	71
750	The Intestinal Microbiome and the Liver Transplant Recipient: What We Know and What We Need to Know. <b>2016</b> , 100, 61-8	30
749	PNPLA3 148M Carriers with Inflammatory Bowel Diseases Have Higher Susceptibility to Hepatic Steatosis and Higher Liver Enzymes. <b>2016</b> , 22, 134-40	18
748	Microbiota and Liver. <b>2016</b> , 25-34	
747	Effect of Lipopolysaccharide on the Progression of Non-Alcoholic Fatty Liver Disease in High Caloric Diet-Fed Mice. <b>2016</b> , 83, 109-18	20
746	When to eat? The influence of circadian rhythms on metabolic health: are animal studies providing the evidence?. <b>2016</b> , 29, 180-193	20
745	Pharmacogenomic and personalized approaches to tackle nonalcoholic fatty liver disease. <b>2016</b> , 17, 1273-1288	10
744	The Effects of Alcohol Intoxication and Burn Injury on the Expression of Claudins and Mucins in the Small and Large Intestines. <b>2016</b> , 45, 73-81	18
743	Sodium butyrate protects mice from the development of the early signs of non-alcoholic fatty liver disease: role of melatonin and lipid peroxidation. <b>2016</b> , 1-12	46
742	Increased Intestinal Permeability and Decreased Barrier Function: Does It Really Influence the Risk of Inflammation?. <b>2016</b> , 1, 135-145	153

741	Transcriptomic differences in intra-abdominal adipose tissue in extremely obese adolescents with different stages of NAFLD. <b>2016</b> , 48, 897-911	6
740	Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease. <b>2016</b> , 22, 1937-44	47
739	Rôles de l'intestin et du foie dans la progression de la stéatopathie métabolique et sa modulation par les acides gras polyinsaturés à longue chaîne n-3. <b>2016</b> , 51, 283-295	
738	Antibiotics as deep modulators of gut microbiota: between good and evil. <b>2016</b> , 65, 1906-1915	273
737	Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota. <b>2016</b> , 311, G1018-G1036	49
736	Critical review evaluating the pig as a model for human nutritional physiology. <b>2016</b> , 29, 60-90	143
735	Treatment with Oxidized Phospholipids Directly Inhibits Nonalcoholic Steatohepatitis and Liver Fibrosis Without Affecting Steatosis. <b>2016</b> , 61, 2545-53	12
734	Early-life enteric infections: relation between chronic systemic inflammation and poor cognition in children. <b>2016</b> , 74, 374-86	49
733	Preterm infant gut microbiota affects intestinal epithelial development in a humanized microbiome gnotobiotic mouse model. <b>2016</b> , 311, G521-32	45
732	Nonalcoholic steatohepatitis heralding olmesartan-induced sprue-like enteropathy. <b>2016</b> , 48, 1399-1401	6
731	Time for paradigm change in management of hepatocellular carcinoma: is a personalized approach on the horizon?. <b>2016</b> , 13, 455-467	10
730	Novel function of histamine signaling via histamine receptors in cholesterol and bile acid metabolism: Histamine H2 receptor protects against nonalcoholic fatty liver disease. <b>2016</b> , 66, 376-85	12
729	Liver disease. <b>2016</b> , 339-349	
728	Promising therapies for treatment of nonalcoholic steatohepatitis. <b>2016</b> , 21, 343-57	23
727	Non-alcoholic fatty liver and the gut microbiota. <b>2016</b> , 5, 782-94	140
726	Pathogenesis and novel treatment options for non-alcoholic steatohepatitis. <b>2016</b> , 1, 56-67	103
725	Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis. <b>2016</b> , 43, 1109-23	31
724	Small intestinal bacterial overgrowth and toll-like receptor signaling in patients with non-alcoholic fatty liver disease. <b>2016</b> , 31, 213-21	94

723	The enteric microbiome in hepatobiliary health and disease. <b>2016</b> , 36, 480-7	22
722	Tissue resident macrophages: Key players in the pathogenesis of type 2 diabetes and its complications. <b>2016</b> , 462, 77-89	75
721	Obesity, NASH, and HCC. <b>2016</b> , 275-286	
720	Involvement of resistin-like molecule $\alpha$ in the development of methionine-choline deficient diet-induced non-alcoholic steatohepatitis in mice. <b>2016</b> , 6, 20157	19
719	Teduglutide and Intestinal Permeability in Short Bowel Syndrome. <b>2016</b> , 40, 1087	1
718	Impact of Dietary Fibers on Nutrient Management and Detoxification Organs: Gut, Liver, and Kidneys. <b>2016</b> , 7, 1111-1121	30
717	Roles of hepatic stellate cells in liver inflammation: a new perspective. <b>2016</b> , 36, 1	37
716	Nonalcoholic Fatty Liver Disease: Pathophysiology and Management. <b>2016</b> , 45, 639-652	117
715	Altered Fecal Microbiota Correlates with Liver Biochemistry in Nonobese Patients with Non-alcoholic Fatty Liver Disease. <b>2016</b> , 6, 32002	156
714	Human Intestinal Barrier Function in Health and Disease. <b>2016</b> , 7, e196	396
713	Of men and microbes. <b>2016</b> , 82-90	
712	The Role of Vitamins in the Pathogenesis of Non-alcoholic Fatty Liver Disease. <b>2016</b> , 11, 19-25	35
711	Changes of Intestinal Functions in Liver Cirrhosis. <b>2016</b> , 1, 24-40	25
710	Nonalcoholic fatty liver disease: Roles of the gut and the liver and metabolic modulation by some dietary factors and especially long-chain n-3 PUFA. <b>2016</b> , 60, 147-59	24
709	TCDD modulation of gut microbiome correlated with liver and immune toxicity in streptozotocin (STZ)-induced hyperglycemic mice. <b>2016</b> , 304, 48-58	43
708	The role of the gut microbiota in NAFLD. <b>2016</b> , 13, 412-25	459
707	Loss of Junctional Adhesion Molecule A Promotes Severe Steatohepatitis in Mice on a Diet High in Saturated Fat, Fructose, and Cholesterol. <b>2016</b> , 151, 733-746.e12	158
706	The metabolic role of the gut microbiota in health and rheumatic disease: mechanisms and interventions. <b>2016</b> , 12, 446-55	85

705	Microbiota Modulation With Synbiotic Decreases Liver Fibrosis in a High Fat Choline Deficient Diet Mice Model of Non-Alcoholic Steatohepatitis (NASH). <b>2016</b> , 23, 132-141	16
704	Gut microbiota-associated bile acid deconjugation accelerates hepatic steatosis in ob/ob mice. <b>2016</b> , 121, 800-10	27
703	Gut-derived lymphocyte recruitment to liver and induce liver injury in non-alcoholic fatty liver disease mouse model. <b>2016</b> , 31, 676-84	19
702	Small Bowel Bacterial Overgrowth in Children. <b>2016</b> , 62, 196-207	23
701	Pu-erh tea extract ameliorates high-fat diet-induced nonalcoholic steatohepatitis and insulin resistance by modulating hepatic IL-6/STAT3 signaling in mice. <b>2016</b> , 51, 819-29	37
700	Nonalcoholic fatty liver disease as trigger of cardiovascular and metabolic complication in metabolic syndrome. <b>2016</b> , 11, 3-10	6
699	Role of MicroRNAs in NAFLD/NASH. <b>2016</b> , 61, 1314-24	58
698	Small Intestine Bacterial Overgrowth and Environmental Enteropathy in Bangladeshi Children. <b>2016</b> , 7, e02102-15	45
697	The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). <b>2016</b> , 65, 1038-48	1227
696	Choline, Its Potential Role in Nonalcoholic Fatty Liver Disease, and the Case for Human and Bacterial Genes. <b>2016</b> , 7, 5-13	94
695	Celiac disease-related hepatic injury: Insights into associated conditions and underlying pathomechanisms. <b>2016</b> , 48, 112-9	34
694	Decreased expression of the glucocorticoid receptor-GILZ pathway in Kupffer cells promotes liver inflammation in obese mice. <b>2016</b> , 64, 916-24	33
693	Pediatric liver diseases: current challenges and future perspectives. <b>2016</b> , 10, 255-65	13
692	Targeting Dysbiosis for the Treatment of Liver Disease. <b>2016</b> , 36, 37-47	30
691	Intestinal microbiota in liver disease. <b>2016</b> , 30, 133-42	46
690	Pathogenesis of NAFLD and NASH. <b>2016</b> , 71-101	4
689	Microbiota, immunity and the liver. <b>2016</b> , 171, 36-49	14
688	Similarities and differences between pediatric and adult nonalcoholic fatty liver disease. <b>2016</b> , 65, 1161-71	43

687	Gut Microbiota of Nonalcoholic Fatty Liver Disease. <b>2016</b> , 61, 1268-81	37
686	Innate Immunity and Inflammation in NAFLD/NASH. <b>2016</b> , 61, 1294-303	208
685	Mechanisms Linking the Gut Microbiome and Glucose Metabolism. <b>2016</b> , 101, 1445-54	100
684	DSS colitis promotes tumorigenesis and fibrogenesis in a choline-deficient high-fat diet-induced NASH mouse model. <b>2016</b> , 470, 15-21	25
683	Influence of Gut Microbiota on Hepatic Lipogenesis and Disease Pathogenesis. <b>2016</b> , 189-209	1
682	Nonalcoholic Fatty Liver Disease and the Gut Microbiome. <b>2016</b> , 20, 263-75	58
681	Exercise and diet in the management of nonalcoholic fatty liver disease. <b>2016</b> , 65, 1172-82	37
680	Genetics of nonalcoholic fatty liver disease. <b>2016</b> , 65, 1026-37	67
679	Nutritional therapy for nonalcoholic fatty liver disease. <b>2016</b> , 29, 1-11	72
678	Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: translational and clinical evidence. <b>2016</b> , 167, 116-24	57
677	The gut microbiota and host health: a new clinical frontier. <b>2016</b> , 65, 330-9	1182
676	Intestinal Microbiota Signatures Associated With Histological Liver Steatosis in Pediatric-Onset Intestinal Failure. <b>2017</b> , 41, 238-248	54
675	Microbiome-Modulated Metabolites at the Interface of Host Immunity. <b>2017</b> , 198, 572-580	171
674	Mechanisms of the prevention and inhibition of the progression and development of non-alcoholic steatohepatitis by genetic and pharmacological decoy receptor 3 supplementation. <b>2017</b> , 47, 1260-1271	7
673	Vitamin D in liver disease: Current evidence and potential directions. <b>2017</b> , 1863, 907-916	23
672	Low-dose acetaminophen induces early disruption of cell-cell tight junctions in human hepatic cells and mouse liver. <b>2017</b> , 7, 37541	22
671	Gut Microbiota and Complications of Liver Disease. <b>2017</b> , 46, 155-169	54
670	Fecal microbiota transplantation in metabolic syndrome: History, present and future. <b>2017</b> , 8, 253-267	144

669	Diet-driven microbiota dysbiosis is associated with vagal remodeling and obesity. <b>2017</b> , 173, 305-317	123
668	Current and future pharmacologic treatment of nonalcoholic steatohepatitis. <b>2017</b> , 33, 134-141	39
667	Type I Interferon Responses Drive Intrahepatic T cells to Promote Metabolic Syndrome. <b>2017</b> , 2,	77
666	Intestinal microbiota and nonalcoholic steatohepatitis. <b>2017</b> , 33, 128-133	90
665	Bacterial infections and hepatic encephalopathy in liver cirrhosis-prophylaxis and treatment. <b>2017</b> , 62, 345-356	16
664	Significant positive association of endotoxemia with histological severity in 237 patients with non-alcoholic fatty liver disease. <b>2017</b> , 46, 175-182	40
663	A synbiotic composed of <i>Lactobacillus fermentum</i> CECT5716 and FOS prevents the development of fatty acid liver and glycemic alterations in rats fed a high fructose diet associated with changes in the microbiota. <b>2017</b> , 61, 1600622	23
662	Non-alcoholic fatty liver disease: A sign of systemic disease. <b>2017</b> , 72, 94-108	92
661	Microbiome and NAFLD: potential influence of aerobic fitness and lifestyle modification. <b>2017</b> , 49, 385-399	18
660	Thermoneutral housing exacerbates nonalcoholic fatty liver disease in mice and allows for sex-independent disease modeling. <b>2017</b> , 23, 829-838	106
659	The intestinal microbiome and paediatric liver disease. <b>2017</b> , 2, 446-455	15
658	Flavanol plasma bioavailability is affected by metabolic syndrome in rats. <b>2017</b> , 231, 287-294	17
657	Effect of miglitol on the suppression of nonalcoholic steatohepatitis development and improvement of the gut environment in a rodent model. <b>2017</b> , 52, 1180-1191	17
656	Dietary sphingolipids: potential for management of dyslipidemia and nonalcoholic fatty liver disease. <b>2017</b> , 75, 274-285	22
655	A cohort study on <i>Helicobacter pylori</i> infection associated with nonalcoholic fatty liver disease. <b>2017</b> , 52, 1201-1210	42
654	Modulation of Gut Microbiota in Pathological States. <b>2017</b> , 3, 83-89	21
653	Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia. <b>2017</b> , 7, 45176	131
652	Remote Sensing between Liver and Intestine: Importance of Microbial Metabolites. <b>2017</b> , 3, 101-113	39

651	Nutritional Approaches to Achieve Weight Loss in Nonalcoholic Fatty Liver Disease. <b>2017</b> , 8, 253-265	23
650	Liver macrophages in tissue homeostasis and disease. <b>2017</b> , 17, 306-321	560
649	Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease. <b>2017</b> , 16, 375-381	217
648	AMP-activated protein kinase: a therapeutic target in intestinal diseases. <b>2017</b> , 7,	31
647	Food contact materials and gut health: Implications for toxicity assessment and relevance of high molecular weight migrants. <b>2017</b> , 109, 1-18	29
646	Environmental/lifestyle factors in the pathogenesis and prevention of type 2 diabetes. <b>2017</b> , 15, 131	212
645	Microbial Factors in Inflammatory Diseases and Cancers. <b>2017</b> , 1024, 153-174	14
644	NAFLD, Helicobacter species and the intestinal microbiome. <b>2017</b> , 31, 657-668	25
643	The role of bariatric surgery in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. <b>2017</b> , 11, 797-811	22
642	Editorial: new insights into the relationship between the intestine and non-alcoholic fatty liver-is "fatty gut" involved in disease progression?. <b>2017</b> , 46, 377-378	4
641	The pharmacological management of NAFLD in children and adolescents. <b>2017</b> , 10, 1225-1237	9
640	Sodium butyrate ameliorates S100/FCA-induced autoimmune hepatitis through regulation of intestinal tight junction and toll-like receptor 4 signaling pathway. <b>2017</b> , 190, 169-176	19
639	Nonalcoholic Fatty Liver Disease. <b>2017</b> , 44, 599-607	24
638	Managing the Burden of Non-NASH NAFLD. <b>2017</b> , 16, 326-334	2
637	The intestinal barrier: a fundamental role in health and disease. <b>2017</b> , 11, 821-834	357
636	The gut microbiome and liver cancer: mechanisms and clinical translation. <b>2017</b> , 14, 527-539	252
635	Gut permeability is related to body weight, fatty liver disease, and insulin resistance in obese individuals undergoing weight reduction. <b>2017</b> , 105, 127-135	80
634	Intestinal gas and liver steatosis: a casual association? A prospective multicentre assessment. <b>2017</b> , 37, 141-147	0

633	Multiple gut-liver axis abnormalities in children with obesity with and without hepatic involvement. <b>2017</b> , 12, 446-452	33
632	Mediterranean diet and nonalcoholic fatty liver disease: molecular mechanisms of protection. <b>2017</b> , 68, 18-27	55
631	Effect of ceramide-1-phosphate transfer protein on intestinal bacterial translocation in severe acute pancreatitis. <b>2017</b> , 41, 86-92	7
630	Nonalcoholic Fatty Liver Disease. <b>2017</b> , 867-908	1
629	Does increased serum d-lactate mean subclinical hyperpermeability of intestinal barrier in middle-aged nonobese males with OSA?. <b>2017</b> , 96, e9144	9
628	Redox Signaling in NASH. <b>2017</b> , 169-180	1
627	Cereal Consumption among Subjects with Celiac Disease: A Snapshot for Nutritional Considerations. <b>2017</b> , 9,	14
626	Short-Term Intake of a Fructose-, Fat- and Cholesterol-Rich Diet Causes Hepatic Steatosis in Mice: Effect of Antibiotic Treatment. <b>2017</b> , 9,	25
625	Hypertension in rats is associated with an increased permeability of the colon to TMA, a gut bacteria metabolite. <b>2017</b> , 12, e0189310	75
624	Gut-Liver Axis Derangement in Non-Alcoholic Fatty Liver Disease. <b>2017</b> , 4,	59
623	A Nutrigenomic Approach to Non-Alcoholic Fatty Liver Disease. <b>2017</b> , 18,	39
622	Connection of Nicotine to Diet-Induced Obesity and Non-Alcoholic Fatty Liver Disease: Cellular and Mechanistic Insights. <b>2017</b> , 8, 23	21
621	Dahuang Zexie Decoction Protects against High-Fat Diet-Induced NAFLD by Modulating Gut Microbiota-Mediated Toll-Like Receptor 4 Signaling Activation and Loss of Intestinal Barrier. <b>2017</b> , 2017, 2945803	14
620	Extracts of <i>Salvia-Nelumbinis Naturalis</i> Ameliorate Nonalcoholic Steatohepatitis via Inhibiting Gut-Derived Endotoxin Mediated TLR4/NF-B Activation. <b>2017</b> , 2017, 9208314	7
619	The Role of Tissue Macrophage-Mediated Inflammation on NAFLD Pathogenesis and Its Clinical Implications. <b>2017</b> , 2017, 8162421	85
618	Nonalcoholic fatty liver disease and bariatric surgery: a comprehensive review. <b>2017</b> , 135, 277-295	19
617	Markers of intestinal permeability are already altered in early stages of non-alcoholic fatty liver disease: Studies in children. <b>2017</b> , 12, e0183282	42
616	Probiotics for the Treatment of Liver Disease. <b>2017</b> , 373-381	3



615	Treatment options for alcoholic and non-alcoholic fatty liver disease: A review. <b>2017</b> , 23, 6549-6570	112
614	Enteropathic Arthritis. <b>2017</b> , 1309-1328	0
613	Role of pregnane X-receptor in regulating bacterial translocation in chronic liver diseases. <b>2017</b> , 9, 1210-1226	11
612	Paediatric fatty liver disease (PeFLD): All is not NAFLD - Pathophysiological insights and approach to management. <b>2018</b> , 68, 1286-1299	26
611	Gut microbiota, fatty liver disease, and hepatocellular carcinoma. <b>2018</b> , 2, 43-51	44
610	Akkermansia muciniphila-derived extracellular vesicles influence gut permeability through the regulation of tight junctions. <b>2018</b> , 50, e450	232
609	Formation of p62-positive inclusion body is associated with macrophage polarization in non-alcoholic fatty liver disease. <b>2018</b> , 48, 757-767	28
608	Elevated systemic zonula occludens 1 is positively correlated with inflammation in cirrhosis. <b>2018</b> , 480, 193-198	9
607	Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Disease: Prevalence and Risk Factors. <b>2018</b> , 24, 1589-1596	33
606	Gut Microbiota-Derived Tryptophan Metabolites Modulate Inflammatory Response in Hepatocytes and Macrophages. <b>2018</b> , 23, 1099-1111	222
605	Effects of inflammatory bowel disease treatment on the risk of nonalcoholic fatty liver disease: a meta-analysis. <b>2018</b> , 30, 854-860	16
604	An objective diagnostic method for inflammatory bowel disease. <b>2018</b> , 5, 180107	4
603	Current State of Knowledge on Implications of Gut Microbiome for Surgical Conditions. <b>2018</b> , 22, 1112-1123	7
602	Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease in adult patients with constipation: The LUBIPRONE, double-blind, randomised, placebo-controlled study design. <b>2018</b> , 69, 40-47	3
601	Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. <b>2018</b> , 41, 328-349	30
600	New insights in gut microbiota and mucosal immunity of the small intestine. <b>2018</b> , 7-8, 23-32	45
599	Organs-on-a-chip: Current applications and consideration points for in vitro ADME-Tox studies. <b>2018</b> , 33, 49-54	61
598	Non-alcoholic fatty liver disease phenotypes in patients with inflammatory bowel disease. <b>2018</b> , 9, 87	39

597	Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease. <b>2018</b> , 13, 321-350	234
596	Peroxiredoxin 4 (PRDX4): Its critical in vivo roles in animal models of metabolic syndrome ranging from atherosclerosis to nonalcoholic fatty liver disease. <b>2018</b> , 68, 91-101	19
595	Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. <b>2018</b> , 14, 99-114	170
594	Tomato Powder Inhibits Hepatic Steatosis and Inflammation Potentially Through Restoring SIRT1 Activity and Adiponectin Function Independent of Carotenoid Cleavage Enzymes in Mice. <b>2018</b> , 62, e1700738	39
593	Microbiota and the liver. <b>2018</b> , 24, 539-550	24
592	Fatty Liver Disease. <b>2018</b> , 451-462	
591	Deletion of both p62 and Nrf2 spontaneously results in the development of nonalcoholic steatohepatitis. <b>2018</b> , 67, 201-218	15
590	Mitochondria in Liver Diseases. <b>2018</b> , 91-126	0
589	Zonulin level, a marker of intestinal permeability, is increased in association with liver enzymes in young adolescents. <b>2018</b> , 481, 218-224	11
588	Helicobacter pylori and Risk of Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. <b>2018</b> , 52, 386-391	32
587	Non-alcoholic fatty liver disease and its treatment with n-3 polyunsaturated fatty acids. <b>2018</b> , 37, 37-55	66
586	New insight into inter-organ crosstalk contributing to the pathogenesis of non-alcoholic fatty liver disease (NAFLD). <b>2018</b> , 9, 164-177	61
585	Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment. <b>2018</b> , 33, 70-85	211
584	The Associations of Endotoxemia With Systemic Inflammation, Endothelial Activation, and Cardiovascular Outcome in Kidney Transplantation. <b>2018</b> , 28, 13-27	4
583	Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis. <b>2018</b> , 57, 861-876	63
582	Microbiota, Liver Diseases, and Alcohol. <b>2017</b> , 5,	12
581	Fecal Microbiota Transplantation: Therapeutic Potential for a Multitude of Diseases beyond. <b>2017</b> , 5,	29
580	Proton pump inhibitors as risk factor for metabolic syndrome and hepatic steatosis in coeliac disease patients on gluten-free diet. <b>2018</b> , 53, 507-516	13

579	High-fat, high-fructose, high-cholesterol feeding causes severe NASH and cecal microbiota dysbiosis in juvenile Ossabaw swine. <b>2018</b> , 314, E78-E92	44
578	The gut-liver axis: impact of a mouse model of small-bowel bacterial overgrowth. <b>2018</b> , 221, 246-256	3
577	Liver disease symptoms in non-alcoholic fatty liver disease and small intestinal bacterial overgrowth. <b>2018</b> , 56, 85-89	8
576	Genetics and epigenetics of NAFLD and NASH: Clinical impact. <b>2018</b> , 68, 268-279	362
575	Association Between Small Intestinal Bacterial Overgrowth by Glucose Breath Test and Coronary Artery Disease. <b>2018</b> , 63, 412-421	13
574	Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease. <b>2018</b> , 175, 469-484	53
573	Molecular Basis for Pathogenesis of Steatohepatitis: Contemporary Understanding and New Insights. <b>2018</b> ,	2
572	Gastroduodenal "Dysbiosis": a New Clinical Entity. <b>2018</b> , 16, 591-604	15
571	Elevated high density lipoprotein cholesterol and low grade systemic inflammation is associated with increased gut permeability in normoglycemic men. <b>2018</b> , 28, 1296-1303	10
570	Non-alcoholic fatty liver disease in underweight patients with inflammatory bowel disease: A case-control study. <b>2018</b> , 13, e0206450	10
569	Non-alcoholic fatty liver disease: a narrative review of genetics. <b>2018</b> , 32, 389-400	24
568	Tight Junction in the Intestinal Epithelium: Its Association with Diseases and Regulation by Phytochemicals. <b>2018</b> , 2018, 2645465	110
567	Modulation of the Gut Microbiota in Rats by Hupan Qingzhi Tablets during the Treatment of High-Fat-Diet-Induced Nonalcoholic Fatty Liver Disease. <b>2018</b> , 2018, 7261619	62
566	Amelioration of hepatic steatosis is associated with modulation of gut microbiota and suppression of hepatic miR-34a in (Thunb.) Makino treated mice. <b>2018</b> , 15, 86	18
565	Intestinal Microbiota Modulation in Obesity-Related Non-alcoholic Fatty Liver Disease. <b>2018</b> , 9, 1813	44
564	Advances in Pediatric Fatty Liver Disease: Pathogenesis, Diagnosis, and Treatment. <b>2018</b> , 47, 949-968	10
563	Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From "two hit theory" to "multiple hit model". <b>2018</b> , 24, 2974-2983	129
562	Roles of Gut-Derived Secretory Factors in the Pathogenesis of Non-Alcoholic Fatty Liver Disease and Their Possible Clinical Applications. <b>2018</b> , 19,	12

561	Colon Epithelial MicroRNA Network in Fatty Liver. <b>2018</b> , 2018, 8246103	0
560	A systematic review of the present and future of non-alcoholic fatty liver disease. <b>2018</b> , 4, 165-174	30
559	Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics. <b>2018</b> , 56, 855-867	21
558	Microbiota, Liver Diseases, and Alcohol. <b>2018</b> , 187-212	1
557	Fecal Microbiota Transplantation: Therapeutic Potential for a Multitude of Diseases beyond Clostridium difficile. <b>2018</b> , 291-308	2
556	Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications. <b>2018</b> , 12, 641-656	51
555	Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. <b>2018</b> , 41, 328-349	1
554	Publisher Correction: The gut-liver axis and the intersection with the microbiome. <b>2018</b> , 15, 785	21
553	The Morbidity and Mortality of Laparoscopic Appendectomy in Patients with Cirrhosis. <b>2018</b> , 11, 1179552217746645	46
552	Chronic moderate alcohol consumption relieves high-fat high-cholesterol diet-induced liver fibrosis in a rat model. <b>2018</b> , 45, 1046-1055	5
551	Genetic and Epigenetic Culprits in the Pathogenesis of Nonalcoholic Fatty Liver Disease. <b>2018</b> , 8, 390-402	17
550	Design and rationale of the INSYTE study: A randomised, placebo controlled study to test the efficacy of a synbiotic on liver fat, disease biomarkers and intestinal microbiota in non-alcoholic fatty liver disease. <b>2018</b> , 71, 113-123	21
549	The role of intestinal microbiota in the pathogenesis of NAFLD: starting points for intervention. <b>2018</b> , 14, 701-706	17
548	The effect of ammonia on canine polymorphonuclear cells. <b>2018</b> , 42, 221-225	1
547	Gut Microbiota as a Driver of Inflammation in Nonalcoholic Fatty Liver Disease. <b>2018</b> , 2018, 9321643	38
546	Microbiota, Obesity and NAFLD. <b>2018</b> , 1061, 111-125	28
545	Daily Consumption of Synbiotic Yogurt Decreases Liver Steatosis in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial. <b>2018</b> , 148, 1276-1284	54
544	Microbiome and Diseases: Hepatic Disorders. <b>2018</b> , 279-293	1

543	Endotoxemia contributes to steatosis, insulin resistance and atherosclerosis in chronic hepatitis C: the role of pro-inflammatory cytokines and oxidative stress. <b>2018</b> , 46, 793-799	10
542	Palmitate-induced lipotoxicity is crucial for the pathogenesis of nonalcoholic fatty liver disease in cooperation with gut-derived endotoxin. <b>2018</b> , 8, 11365	46
541	Diammonium Glycyrrhizinate Protects against Nonalcoholic Fatty Liver Disease in Mice through Modulation of Gut Microbiota and Restoration of Intestinal Barrier. <b>2018</b> , 15, 3860-3870	41
540	Oral administration of fructose exacerbates liver fibrosis and hepatocarcinogenesis via increased intestinal permeability in a rat steatohepatitis model. <b>2018</b> , 9, 28638-28651	14
539	Intestinal Microbiome Shifts, Dysbiosis, Inflammation, and Non-alcoholic Fatty Liver Disease. <b>2018</b> , 9, 61	83
538	Bifidobacteria and lactobacilli in the gut microbiome of children with non-alcoholic fatty liver disease: which strains act as health players?. <b>2018</b> , 14, 81-87	55
537	Mucus: An Underestimated Gut Target for Environmental Pollutants and Food Additives. <b>2018</b> , 6,	35
536	Increased risk of nonalcoholic fatty liver disease in patients with coeliac disease on a gluten-free diet: beyond traditional metabolic factors. <b>2018</b> , 48, 538-546	26
535	iTRAQ-based quantitative proteomic analysis of alterations in the intestine of Hu sheep under weaning stress. <b>2018</b> , 13, e0200680	7
534	The gut-liver axis and the intersection with the microbiome. <b>2018</b> , 15, 397-411	465
533	Toll-Like Receptor-7 Signaling Promotes Nonalcoholic Steatohepatitis by Inhibiting Regulatory T Cells in Mice. <b>2018</b> , 188, 2574-2588	23
532	Association between cagA negative Helicobacter pylori status and nonalcoholic fatty liver disease among adults in the United States. <b>2018</b> , 13, e0202325	16
531	Chronic calcitriol supplementation improves the inflammatory profiles of circulating monocytes and the associated intestinal/adipose tissue alteration in a diet-induced steatohepatitis rat model. <b>2018</b> , 13, e0194867	7
530	Gut inflammation exacerbates hepatic injury in the high-fat diet induced NAFLD mouse: Attention to the gut-vascular barrier dysfunction. <b>2018</b> , 209, 157-166	35
529	Volatile Oil of Inhibits Nonalcoholic Fatty Liver Disease via the Gut-Liver Axis. <b>2018</b> , 2018, 3589874	10
528	Variation in the Plasma Levels of Polyunsaturated Fatty Acids in Control vis-à-vis Nonalcoholic Fatty Liver Disease Subjects and Its Possible Association with Gut Microbiome. <b>2018</b> , 16, 329-335	2
527	Non-Alcoholic Fatty Liver Disease. <b>2018</b> , 540-560	
526	Enterobacter cloacae administration induces hepatic damage and subcutaneous fat accumulation in high-fat diet fed mice. <b>2018</b> , 13, e0198262	13

525	Profiling the Gut Microbiome: Practice and Potential. <b>2019</b> , 200-217	
524	The Aryl Hydrocarbon Receptor (AhR) Mediates the Counter-Regulatory Effects of Pelargonidins in Models of Inflammation and Metabolic Dysfunctions. <b>2019</b> , 11,	19
523	Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development. <b>2019</b> , 71, 1216-1228	163
522	Recent Insights Into the Multiple Pathways Driving Non-alcoholic Steatohepatitis-Derived Hepatocellular Carcinoma. <b>2019</b> , 9, 762	20
521	Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease. <b>2019</b> , 50, 628-639	19
520	Role of Bile Acids in Dysbiosis and Treatment of Nonalcoholic Fatty Liver Disease. <b>2019</b> , 2019, 7659509	23
519	Probiotics for dietary management of non-alcoholic fatty liver disease. <b>2019</b> , 17, 1553-1563	8
518	Porphyromonas gingivalis-derived lipopolysaccharide causes excessive hepatic lipid accumulation via activating NF- $\kappa$ B and JNK signaling pathways. <b>2019</b> , 25, 1789-1797	14
517	Jlus66 extenuate oxidative stress and inflammation via regulation of intestinal flora in rats with non alcoholic fatty liver disease. <b>2019</b> , 7, 2636-2646	17
516	A review of synbiotic efficacy in non-alcoholic fatty liver disease as a therapeutic approach. <b>2019</b> , 13, 2917-2922	15
515	Non-alcoholic Fatty Liver in the Pathogenesis of Diabetes. <b>2019</b> , 227-235	
514	Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. <b>2019</b> , 25, 1096-1103	650
513	Insights into the evolving role of the gut microbiome in nonalcoholic fatty liver disease: rationale and prospects for therapeutic intervention. <b>2019</b> , 12, 1756284819858470	12
512	Effect of probiotic supplementation in nonalcoholic steatohepatitis patients: PROBILIVER TRIAL protocol. <b>2019</b> , 20, 580	5
511	Dietary lipids, gut microbiota and lipid metabolism. <b>2019</b> , 20, 461-472	189
510	The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies. <b>2019</b> , 11,	42
509	Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far?. <b>2019</b> , 7,	44
508	Effects of Resistant Starch Supplementation on Glucose Metabolism, Lipid Profile, Lipid Peroxidation Marker, and Oxidative Stress in Overweight and Obese Adults: Randomized, Double-Blind, Crossover Trial. <b>2019</b> , 8, 318-328	5

507	Liver DCs in health and disease. <b>2019</b> , 348, 263-299	4
506	A narrative review of factors associated with the development and progression of non-alcoholic fatty liver disease. <b>2019</b> , 1, 180	3
505	Raw Bowl Tea (Tuocha) Polyphenol Prevention of Nonalcoholic Fatty Liver Disease by Regulating Intestinal Function in Mice. <b>2019</b> , 9,	30
504	Gut Dysfunction and Non-alcoholic Fatty Liver Disease. <b>2019</b> , 10, 611	45
503	Relationship between Changes in Microbiota and Liver Steatosis Induced by High-Fat Feeding-A Review of Rodent Models. <b>2019</b> , 11,	17
502	Protective effects of <i>Lactobacillus plantarum</i> against chronic alcohol-induced liver injury in the murine model. <b>2019</b> , 103, 8597-8608	12
501	Mesenteric lymph node CD4 T lymphocytes migrate to liver and contribute to non-alcoholic fatty liver disease. <b>2019</b> , 337, 33-41	11
500	Disruption of Intestinal Homeostasis and Intestinal Microbiota During Experimental Autoimmune Uveitis. <b>2019</b> , 60, 420-429	34
499	Role of gut microbial metabolites in nonalcoholic fatty liver disease. <b>2019</b> , 20, 181-188	12
498	The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). <b>2019</b> , 76, 1541-1558	161
497	Drinking for protection? Epidemiological and experimental evidence on the beneficial effects of coffee or major coffee compounds against gastrointestinal and liver carcinogenesis. <b>2019</b> , 123, 567-589	27
496	Fecal microbiota transplantation beyond <i>Clostridioides difficile</i> infections. <b>2019</b> , 44, 716-729	55
495	Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications. <b>2019</b> , 50, 144-158	26
494	Mitochondria-Mediated Pathogenesis and Therapeutics for Non-Alcoholic Fatty Liver Disease. <b>2019</b> , 63, e1900043	20
493	Paediatricians play a key role in preventing early harmful events that could permanently influence the development of the gut microbiota in childhood. <b>2019</b> , 108, 1942-1954	5
492	Role of Gut Microbiota in Hepatocarcinogenesis. <b>2019</b> , 7,	56
491	The role of gut microbiota in liver disease development and treatment. <b>2019</b> , 3, 3-18	24
490	Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH). <b>2019</b> , 18, 416-421	28

489	Metformin attenuates the onset of non-alcoholic fatty liver disease and affects intestinal microbiota and barrier in small intestine. <b>2019</b> , 9, 6668	43
488	Blood-Bile Barrier: Morphology, Regulation, and Pathophysiology. <b>2019</b> , 19, 69-87	15
487	From NASH to HCC: current concepts and future challenges. <b>2019</b> , 16, 411-428	425
486	Contribution of the gut microbiota to the regulation of host metabolism and energy balance: a focus on the gut-liver axis. <b>2019</b> , 78, 319-328	44
485	Role of intestinal microecology in the regulation of energy metabolism by dietary polyphenols and their metabolites. <b>2019</b> , 63,	40
484	Current Models of Fatty Liver Disease; New Insights, Therapeutic Targets and Interventions. <b>2019</b> , 1134, 33-58	1
483	Clinical Conditions Associated With Bacterial Overgrowth. <b>2019</b> , 67-83	5
482	Indoles: metabolites produced by intestinal bacteria capable of controlling liver disease manifestation. <b>2019</b> , 286, 32-40	53
481	Nonalcoholic fatty liver disease and the gut microbiome: Are bacteria responsible for fatty liver?. <b>2019</b> , 244, 408-418	9
480	Fructose Promotes Leaky Gut, Endotoxemia, and Liver Fibrosis Through Ethanol-Inducible Cytochrome P450-2E1-Mediated Oxidative and Nitrative Stress. <i>Hepatology</i> , <b>2021</b> , 73, 2180-2195	11.2 59
479	Overuse of antianaerobic drug is associated with poor postchemotherapy prognosis of patients with hepatocellular carcinoma. <b>2019</b> , 145, 2701-2711	13
478	Vascular syndromes in liver cirrhosis. <b>2019</b> , 12, 387-397	14
477	The Inhibitory T Cell Receptors PD1 and 2B4 Are Differentially Regulated on CD4 and CD8 T Cells in a Mouse Model of Non-alcoholic Steatohepatitis. <b>2019</b> , 10, 244	1
476	Gut Microbiota-Derived Mediators as Potential Markers in Nonalcoholic Fatty Liver Disease. <b>2019</b> , 2019, 8507583	20
475	The Microbiome and Metabolome in Nonalcoholic Fatty Liver Disease. <b>2019</b> , 265-269	
474	Probiotics as a Dietary Intervention for Reducing the Risk of Nonalcoholic Fatty Liver Disease. <b>2019</b> , 207-223	3
473	Beneficial effects of CNCM I-745 on clinical disorders associated with intestinal barrier disruption. <b>2019</b> , 12, 67-82	31
472	The Role of Gut-Derived Microbial Antigens on Liver Fibrosis Initiation and Progression. <b>2019</b> , 8,	19



471	Dietary Patterns and Components in Nonalcoholic Fatty Liver Disease (NAFLD): What Key Messages Can Health Care Providers Offer?. <b>2019</b> , 11,	19
470	Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?. <b>2019</b> , 11,	23
469	The gut microbiota: a new perspective on the toxicity of malachite green (MG). <b>2019</b> , 103, 9723-9737	8
468	The promising role of probiotic and synbiotic therapy in aminotransferase levels and inflammatory markers in patients with nonalcoholic fatty liver disease - a systematic review and meta-analysis. <b>2019</b> , 31, 703-715	9
467	Small Intestinal Bacterial Overgrowth in Patients With Cirrhosis. <b>2019</b> , 9, 257-267	20
466	Endotoxin regulates matrix genes increasing reactive oxygen species generation by intercellular communication between palmitate-treated hepatocyte and stellate cell. <b>2018</b> , 234, 122-133	3
465	Current and Emerging Therapies for Non-alcoholic Fatty Liver Disease. <b>2019</b> , 79, 75-84	13
464	Consumption of decaffeinated coffee protects against the development of early non-alcoholic steatohepatitis: Role of intestinal barrier function. <b>2019</b> , 21, 101092	15
463	The role of the microbiome in NAFLD and NASH. <b>2019</b> , 11,	185
462	Antimicrobial proteins: intestinal guards to protect against liver disease. <b>2019</b> , 54, 209-217	21
461	The Role of the Mycobiota in the Gut-Liver Axis. <b>2019</b> , 133-145	1
460	Adult Non-alcoholic Fatty Liver Disease (NAFLD). <b>2019</b> , 23-46	
459	The Role of the Bacterial Microbiota in Alcoholic and Non-alcoholic Fatty Liver Disease. <b>2019</b> , 89-104	
458	Intestinally derived bacterial products stimulate development of nonalcoholic steatohepatitis. <b>2019</b> , 141, 418-428	7
457	Intestinal Microbiota Protects against MCD Diet-Induced Steatohepatitis. <b>2019</b> , 20,	19
456	Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis. <b>2019</b> , 4, 492-503	126
455	Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease. <b>2019</b> , 13, 193-204	39
454	Molecular pathways of nonalcoholic fatty liver disease development and progression. <b>2019</b> , 76, 99-128	179

453	Combining probiotics and an angiotensin-II type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non-alcoholic steatohepatitis. <b>2019</b> , 49, 284-295	15
452	Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH. <b>2019</b> , 103, e1-e13	112
451	Potential mechanisms linking gut microbiota and portal hypertension. <b>2019</b> , 39, 598-609	20
450	Targeting mitochondria to oppose the progression of nonalcoholic fatty liver disease. <b>2019</b> , 160, 34-45	29
449	Advancing the understanding of NAFLD to hepatocellular carcinoma development: From experimental models to humans. <b>2019</b> , 1871, 117-125	33
448	Obesity and Metabolic Syndrome in Kidney Transplantation: The Role of Dietary Fructose and Systemic Endotoxemia. <b>2019</b> , 103, 191-201	2
447	Non-alcoholic fatty liver disease and obesity: the role of the gut bacteria. <b>2019</b> , 58, 1771-1784	19
446	Emerging Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function. <b>2019</b> , 17, 296-306	78
445	Platelet number in different anticoagulants as a diagnostic biomarker for increased intestinal permeability. <b>2020</b> , 31, 242-247	
444	Unravelling fatty liver haemorrhagic syndrome: 2. Inflammation and pathophysiology. <b>2020</b> , 49, 131-143	6
443	Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. <b>2020</b> , 41,	56
442	The gut-liver axis in liver disease: Pathophysiological basis for therapy. <b>2020</b> , 72, 558-577	300
441	The intestinal microbiota fuelling metabolic inflammation. <b>2020</b> , 20, 40-54	301
440	Requirements for designing organ-on-a-chip platforms to model the pathogenesis of liver disease. <b>2020</b> , 181-213	2
439	Lower gut microbiome diversity and higher abundance of proinflammatory genus are associated with biopsy-proven nonalcoholic steatohepatitis. <b>2020</b> , 11, 569-580	49
438	Role of gut microbiota in liver disease. <b>2020</b> , 318, G84-G98	35
437	Drug discovery and treatment paradigms in nonalcoholic steatohepatitis. <b>2020</b> , 3, e00105	10
436	The gut-liver-kidney axis: Novel regulator of fatty liver associated chronic kidney disease. <b>2020</b> , 152, 104617	23

435	The influence of dietary patterns on gut microbiome and its consequences for nonalcoholic fatty liver disease. <b>2020</b> , 96, 135-144	3
434	Association between serum folate levels and fatty liver disease. <b>2020</b> , 29, 30-35	3
433	Chinese Sweet Leaf Tea () Mitigates LPS-Induced Low-Grade Chronic Inflammation and Reduces the Risk of Metabolic Disorders in a C57BL/6J Mouse Model. <b>2020</b> , 68, 138-146	12
432	Amelioration of non-alcoholic steatohepatitis by Qushi Huayu decoction is associated with inhibition of the intestinal mitogen-activated protein kinase pathway. <b>2020</b> , 66, 153135	13
431	The regulatory effects of phytosterol esters (PSEs) on gut flora and faecal metabolites in rats with NAFLD. <b>2020</b> , 11, 977-991	17
430	Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives. <b>2020</b> , 55, 142-158	41
429	Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease: a systematic review and meta-analysis. <b>2020</b> , 32, 601-608	19
428	Anti-NASH Drug Development Hitches a Lift on PPAR Agonism. <b>2019</b> , 9,	47
427	Gut inflammation exacerbates hepatic injury in C57BL/6J mice gut-vascular barrier dysfunction with high-fat-incorporated meat protein diets. <b>2020</b> , 11, 9168-9176	3
426	The role of the gut microbiome and exercise in non-alcoholic fatty liver disease. <b>2020</b> , 13, 1756284820941745	6
425	The pharmacological treatment of nonalcoholic fatty liver disease in children. <b>2020</b> , 13, 1219-1227	2
424	Gut Microbiota and Immune System Interactions. <b>2020</b> , 8,	85
423	Intestinal permeability in human nonalcoholic fatty liver disease: A systematic review and meta-analysis. <b>2020</b> , 40, 2906-2916	24
422	Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial. <b>2020</b> , 5, 996-1007	7
421	From obesity through gut microbiota to cardiovascular diseases: a dangerous journey. <b>2020</b> , 10, 35-49	15
420	Ameliorative effects and molecular mechanisms of vine tea on western diet-induced NAFLD. <b>2020</b> , 11, 5976-5991	20
419	Non-alcoholic fatty liver disease in inflammatory bowel disease patients. <b>2020</b> , 32, 903-906	6
418	Can You Trust Your Gut? Implicating a Disrupted Intestinal Microbiome in the Progression of NAFLD/NASH. <b>2020</b> , 11, 592157	8

4 <sup>17</sup>	Intestinal permeability and bacterial translocation in patients with liver disease, focusing on alcoholic aetiology: methods of assessment and therapeutic intervention. <b>2020</b> , 13, 1756284820942616	7
4 <sup>16</sup>	Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. <b>2021</b> , 50, 101122	23
4 <sup>15</sup>	Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis. <b>2020</b> , 21,	8
4 <sup>14</sup>	Gut Microbiota and Liver Interaction through Immune System Cross-Talk: A Comprehensive Review at the Time of the SARS-CoV-2 Pandemic. <b>2020</b> , 9,	15
4 <sup>13</sup>	The Relationship between Choline Bioavailability from Diet, Intestinal Microbiota Composition, and Its Modulation of Human Diseases. <b>2020</b> , 12,	25
4 <sup>12</sup>	Human microbiome is a diagnostic biomarker in hepatocellular carcinoma. <b>2020</b> , 19, 109-115	11
4 <sup>11</sup>	Genetic susceptibility of increased intestinal permeability is associated with progressive liver disease and diabetes in patients with non-alcoholic fatty liver disease. <b>2020</b> , 30, 2103-2110	3
4 <sup>10</sup>	Computational Modeling of Fructose Metabolism and Development in NAFLD. <b>2020</b> , 8, 762	2
4 <sup>09</sup>	Advances in the Involvement of Gut Microbiota in Pathophysiology of NAFLD. <b>2020</b> , 7, 361	16
4 <sup>08</sup>	Rhubarb Enema Improved Colon Mucosal Barrier Injury in 5/6 Nephrectomy Rats May Associate With Gut Microbiota Modification. <b>2020</b> , 11, 1092	15
4 <sup>07</sup>	The effects of Bacillus coagulans supplementation in patients with non-alcoholic fatty liver disease: A randomized, placebo-controlled, clinical trial. <b>2020</b> , 39, 53-60	9
4 <sup>06</sup>	Chinese Medicinal Herbs Targeting the Gut-Liver Axis and Adipose Tissue-Liver Axis for Non-Alcoholic Fatty Liver Disease Treatments: The Ancient Wisdom and Modern Science. <b>2020</b> , 11, 572729	6
4 <sup>05</sup>	Prebiotics and type 2 diabetes: targeting the gut microbiota for improved glycaemic control?. <b>2020</b> , 37, 133-137	2
4 <sup>04</sup>	Association of worsening of nonalcoholic fatty liver disease with cardiometabolic function and intestinal bacterial overgrowth: A cross-sectional study. <b>2020</b> , 15, e0237360	2
4 <sup>03</sup>	The role of probiotics on the roadmap to a healthy microbiota: a symposium report. <b>2020</b> , 1,	1
4 <sup>02</sup>	Liver Steatosis, Gut-Liver Axis, Microbiome and Environmental Factors. A Never-Ending Bidirectional Cross-Talk. <b>2020</b> , 9,	40
4 <sup>01</sup>	High-Risk Groups for Non-alcoholic Fatty Liver and Non-alcoholic Steatohepatitis Development and Progression. <b>2020</b> , 19, 412-419	4
4 <sup>00</sup>	Gut Microbiota and Intestinal Trans-Epithelial Permeability. <b>2020</b> , 21,	42

399	New Insights into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative Stress. <b>2020</b> , 12,	31
398	Three-tissue microphysiological system for studying inflammatory responses in gut-liver Axis. <b>2020</b> , 22, 65	5
397	Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH. <b>2020</b> , 21,	20
396	History of Nonalcoholic Fatty Liver Disease. <b>2020</b> , 21,	30
395	Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review. <b>2020</b> , 21,	6
394	Multiple organs involved in the pathogenesis of non-alcoholic fatty liver disease. <b>2020</b> , 10, 140	9
393	Host miRNA-21 promotes liver dysfunction by targeting small intestinal in mice. <b>2020</b> , 12, 1-18	8
392	Intestinal Barrier Function in Health and Disease-Any role of SARS-CoV-2?. <b>2020</b> , 8,	14
391	Gut Microbiota, Peroxisome Proliferator-Activated Receptors, and Hepatocellular Carcinoma. <b>2020</b> , 7, 271-288	6
390	The Molecular and Mechanistic Insights Based on Gut-Liver Axis: Nutritional Target for Non-Alcoholic Fatty Liver Disease (NAFLD) Improvement. <b>2020</b> , 21,	24
389	Effects of berberine on intestinal flora of Non-alcoholic fatty liver induced by High-fat diet through 16S rRNA gene segmentation. <b>2020</b> , 32, 2603-2609	4
388	The Influence of Small Intestinal Bacterial Overgrowth in Digestive and Extra-Intestinal Disorders. <b>2020</b> , 21,	11
387	Bisphenol A exposure induces gut microbiota dysbiosis and consequent activation of gut-liver axis leading to hepatic steatosis in CD-1 mice. <b>2020</b> , 265, 114880	31
386	Combined alcoholic and non-alcoholic steatohepatitis. <b>2020</b> , 2, 100101	15
385	Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand?. <b>2020</b> , 6, 9	25
384	High Prevalence and Gender-Related Differences of Gastrointestinal Manifestations in a Cohort of DM1 Patients: A Perspective, Cross-Sectional Study. <b>2020</b> , 11, 394	3
383	Blocking integrin $\beta$ -mediated CD4 T cell recruitment to the intestine and liver protects mice from western diet-induced non-alcoholic steatohepatitis. <b>2020</b> , 73, 1013-1022	21
382	Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders. <b>2020</b> , 159, 849-863	62

381	Sex-specific maternal calcium requirements for the prevention of nonalcoholic fatty liver disease by altering the intestinal microbiota and lipid metabolism in the high-fat-diet-fed offspring mice. <b>2020</b> , 11, 1590-1607	0
380	Chemotherapy-associated liver injury in colorectal cancer. <b>2020</b> , 13, 1756284820924194	11
379	The critical role of Faecalibacterium prausnitzii in human health: An overview. <b>2020</b> , 149, 104344	37
378	Endogenous ethanol produced by intestinal bacteria induces mitochondrial dysfunction in non-alcoholic fatty liver disease. <b>2020</b> , 35, 2009-2019	14
377	A story of liver and gut microbes: how does the intestinal flora affect liver disease? A review of the literature. <b>2020</b> , 318, G889-G906	43
376	Impact of global PTP1B deficiency on the gut barrier permeability during NASH in mice. <b>2020</b> , 35, 100954	3
375	Hepatocellular carcinoma in the context of non-alcoholic steatohepatitis (NASH): recent advances in the pathogenic mechanisms. <b>2020</b> , 41,	3
374	Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial. <b>2020</b> , 115, 1055-1065	72
373	Host microbiota dictates the proinflammatory impact of LPS in the murine liver. <b>2020</b> , 67, 104920	7
372	Effect of liver transplantation on intestinal permeability and correlation with infection episodes. <b>2020</b> , 15, e0235359	1
371	The Gut-liver Axis in Immune Remodeling: New insight into Liver Diseases. <b>2020</b> , 16, 2357-2366	24
370	Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity?. <b>2020</b> , 158, 1881-1898	38
369	Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma. <b>2020</b> , 21,	31
368	Increased Colonic Permeability and Lifestyles as Contributing Factors to Obesity and Liver Steatosis. <b>2020</b> , 12,	19
367	Bile acid sequestration reverses liver injury and prevents progression of nonalcoholic steatohepatitis in Western diet-fed mice. <b>2020</b> , 295, 4733-4747	20
366	Fructo-oligosaccharides ameliorate steatohepatitis, visceral adiposity, and associated chronic inflammation via increased production of short-chain fatty acids in a mouse model of non-alcoholic steatohepatitis. <b>2020</b> , 20, 46	12
365	The complex puzzle of dietary silver nanoparticles, mucus and microbiota in the gut. <b>2020</b> , 23, 69-89	10
364	Diet, Gut Microbiota and Non-Alcoholic Fatty Liver Disease: Three Parts of the Same Axis. <b>2020</b> , 9,	29

363	Idiopathic pulmonary fibrosis is associated with tight junction protein alterations. <b>2020</b> , 1862, 183205	12
362	Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH. <b>2020</b> , 318, G582-G609	15
361	Western diet-induced increase in colonic bile acids compromises epithelial barrier in nonalcoholic steatohepatitis. <b>2020</b> , 34, 7089-7102	17
360	Phenotyping non-alcoholic fatty liver disease by the gut microbiota: Ready for prime time?. <b>2020</b> , 35, 1969-1977	11
359	Endotoxin Producers Overgrowing in Human Gut Microbiota as the Causative Agents for Nonalcoholic Fatty Liver Disease. <b>2020</b> , 11,	48
358	Intestinal barrier function and metabolic/liver diseases. <b>2020</b> , 4, 81-87	10
357	Modulation of the gut microbiota represents a new management for non-alcoholic fatty liver disease. <b>2020</b> , 9, 223-226	3
356	Pathogenesis and pathways: nonalcoholic fatty liver disease & alcoholic liver disease. <b>2020</b> , 5, 49	7
355	Celiac Disease, Gluten-Free Diet, and Metabolic and Liver Disorders. <b>2020</b> , 12,	12
354	Gut microbiota abnormalities, small intestinal bacterial overgrowth, and non-alcoholic fatty liver disease: An emerging paradigm. <b>2020</b> , 39, 9-21	18
353	Berberine ameliorates intestinal mucosal barrier dysfunction in nonalcoholic fatty liver disease (NAFLD) rats. <b>2020</b> , 32, 2534-2539	2
352	Increased risk of acute liver failure by pain killer drugs in NAFLD: Focus on nuclear receptors and their coactivators. <b>2021</b> , 53, 26-34	5
351	Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications. <b>2021</b> , 18, 117-135	16
350	Pharmacological activation of REV-ERB $\beta$ improves nonalcoholic steatohepatitis by regulating intestinal permeability. <b>2021</b> , 114, 154409	11
349	Probiotics as Live Bio-therapeutics: Prospects and Perspectives. <b>2021</b> , 83-120	2
348	Nonalcoholic fatty liver disease (NAFLD) severity is associated to a nonhemostatic contribution and proinflammatory phenotype of platelets. <b>2021</b> , 231, 24-38	8
347	Current Concepts, Opportunities, and Challenges of Gut Microbiome-Based Personalized Medicine in Nonalcoholic Fatty Liver Disease. <b>2021</b> , 33, 21-32	37
346	Metabolic-associated fatty liver disease (MAFLD) in coeliac disease. <b>2021</b> , 41, 788-798	5

- 345 Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. **2021**, 18, 223-238 228
- 344 Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy?. **2021**, 15, 51-64 3
- 343 Proton pump inhibitors use and the risk of fatty liver disease: A nationwide cohort study. **2021**, 36, 1235-1243 3
- 342 The Mechanism of Nonalcoholic Fatty Liver Disease Induced by Helicobacter pylori Infection. **2021**, 11, 3865-3869
- 341 Contribution of the Microbiota to Healthy Aging. **2021**,
- 340 Prebiotic Impacts of Soybean Residue (Okara) on Eubiosis/Dysbiosis Condition of the Gut and the Possible Effects on Liver and Kidney Functions. **2021**, 26, 11
- 339 The inflammation during colorectal cancer: A friend or a foe?. **2021**, 103-129 0
- 338 A nutritional intervention that promotes increased vegetable intake in Japanese with non-alcoholic fatty liver disease: a six-month trial.. **2022**, 70, 46-53 1
- 337 Modeling dysbiosis of human NASH in mice: Loss of gut microbiome diversity and overgrowth of Erysipelotrichales. **2021**, 16, e0244763 6
- 336 H. pylori is related to NAFLD but only in female: A Cross-sectional Study. **2021**, 18, 2303-2311 3
- 335 New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease. **2021**, 41, 87-102 0
- 334 Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease. **2021**, 7, 11 7
- 333 Non-Alcoholic Fatty Liver Disease: From Pathogenesis to Clinical Impact. **2021**, 9, 135 14
- 332 The Role of Gut Microbiota Dysbiosis in Gastrointestinal Carcinogenesis. **2021**,
- 331 Emerging prevalence of fatty liver disease in HIV. **2021**, 16, 59-73 0
- 330 The gut/liver axis, inflammation, and the pathogenesis of metabolic syndrome. **2021**, 93-107
- 329 Val-Val-Tyr-Pro protects against non-alcoholic steatohepatitis in mice by modulating the gut microbiota and gut-liver axis activation. **2021**, 25, 1439-1455 3
- 328 Comparison of gut microbiota structure and Actinobacteria abundances in healthy young adults and elderly subjects: a pilot study. **2021**, 21, 13 4



327	Gut Microbiome and Liver Cancer. <b>2021</b> , 199-255	
326	THE ROLE OF ZONULIN IN THE DEVELOPMENT OF LIVER FIBROSIS IN OBESE ADOLESCENTS. <b>2021</b> , 74, 77-82	
325	Inflammatory Mechanisms Underlying Nonalcoholic Steatohepatitis and the Transition to Hepatocellular Carcinoma. <b>2021</b> , 13,	13
324	Effects of traditional Chinese medicine Chaihu-Shugan-San aqueous extract on high-fat diet-induced liver steatosis in rats via intestinal microbiota metabolite SCFAs and its receptor Gpr43/109a. 1	
323	Dietary approaches to managing nonalcoholic fatty liver disease. <b>2021</b> , 46, 19-26	0
322	Cognitive Dysfunction in Non-Alcoholic Fatty Liver Disease-Current Knowledge, Mechanisms and Perspectives. <b>2021</b> , 10,	11
321	Insights into the Impact of Microbiota in the Treatment of NAFLD/NASH and Its Potential as a Biomarker for Prognosis and Diagnosis. <b>2021</b> , 9,	7
320	Metabolic regulation mechanism of fucoidan via intestinal microecology in diseases. <b>2021</b> , 101, 4456-4463	4
319	Gut Microbiota in Metabolic-associated Fatty Liver Disease and in Other Chronic Metabolic Diseases. <b>2021</b> , 9, 227-238	4
318	DSS-induced colitis is associated with adipose tissue dysfunction and disrupted hepatic lipid metabolism leading to hepatosteatosis and dyslipidemia in mice. <b>2021</b> , 11, 5283	11
317	Gut-Liver Axis in Nonalcoholic Fatty Liver Disease: the Impact of the Metagenome, End Products, and the Epithelial and Vascular Barriers. <b>2021</b> , 41, 191-205	4
316	Modulation of serotonin in the gut-liver neural axis ameliorates the fatty and fibrotic changes in non-alcoholic fatty liver. <b>2021</b> , 14,	5
315	Bile salt hydrolases deplete conjugated bile acids and erode gut barrier integrity in non-alcoholic steatohepatitis.	0
314	Functional Foods for the Management of Non-Alcoholic Fatty Liver Disease.	0
313	Bacterial and eukaryotic extracellular vesicles and nonalcoholic fatty liver disease: new players in the gut-liver axis?. <b>2021</b> , 320, G485-G495	5
312	A randomised placebo controlled trial of VSL#3 probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease. <b>2021</b> , 21, 144	5
311	The Role of the Gut-Liver Axis in Metabolic Dysfunction-Associated Fatty Liver Disease. <b>2021</b> , 12, 660179	13
310	Dietary anthocyanins as potential natural modulators for the prevention and treatment of non-alcoholic fatty liver disease: A comprehensive review. <b>2021</b> , 142, 110180	16

309	Role of the gut microbiota in type 2 diabetes and related diseases. <b>2021</b> , 117, 154712	32
308	Affects Expression of Circadian Clock Genes in Human Hepatoma Cells. <b>2021</b> , 9,	4
307	NAFLD and Infection, a Nuanced Relationship. <b>2021</b> , 2021, 5556354	8
306	Role of Insulin Resistance in MAFLD. <b>2021</b> , 22,	16
305	Non-alcoholic fatty liver disease is associated with bacterial translocation and a higher inflammation response in psoriatic patients. <b>2021</b> , 11, 8593	5
304	Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC. <b>2021</b> , 22,	9
303	Small intestinal bacterial overgrowth and orocecal transit time in patients of nonalcoholic fatty liver disease. <b>2021</b> ,	2
302	Targeting the Gut Microbiota for Remediating Obesity and Related Metabolic Disorders. <b>2021</b> , 151, 1703-1716	1
301	Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?. <b>2021</b> , 22,	17
300	Gut Microbiome and Metabolites in Patients with NAFLD and after Bariatric Surgery: A Comprehensive Review. <b>2021</b> , 11,	3
299	Partially hydrolyzed guar gum attenuates non-alcoholic fatty liver disease in mice through the gut-liver axis. <b>2021</b> , 27, 2160-2176	4
298	Early Life Exposure to Food Contaminants and Social Stress as Risk Factor for Metabolic Disorders Occurrence?-An Overview. <b>2021</b> , 11,	1
297	Immunomodulatory role of Faecalibacterium prausnitzii in obesity and metabolic disorders. <b>2021</b> , 33,	1
296	Non-alcoholic fatty liver disease in obese children and adolescents: a role for nutrition?. <b>2021</b> ,	7
295	The Role of the Microbiome in Liver Cancer. <b>2021</b> , 13,	4
294	Intestinal Permeability Is a Mechanical Rheostat in the Pathogenesis of Liver Cirrhosis. <b>2021</b> , 22,	5
293	Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut-Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy. <b>2021</b> , 22,	7
292	The Emerging Role of B Cells in the Pathogenesis of NAFLD. <i>Hepatology</i> , <b>2021</b> , 74, 2277-2286	11.2 8

291	Intestinal Dysbiosis and Non-Alcoholic Fatty Liver Disease.	1
290	Diagnosis and management of secondary causes of steatohepatitis. <b>2021</b> , 74, 1455-1471	13
289	Unhealthy Lifestyle and Gut Dysbiosis: A Better Understanding of the Effects of Poor Diet and Nicotine on the Intestinal Microbiome. <b>2021</b> , 12, 667066	15
288	Herbal therapy for ameliorating nonalcoholic fatty liver disease via rebuilding the intestinal microecology. <b>2021</b> , 16, 62	1
287	The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target. <b>2021</b> , 22,	4
286	A Comprehensive Review of Transaminitis and Irritable Bowel Syndrome. <b>2021</b> , 13, e16583	2
285	Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease. <b>2021</b> ,	3
284	Effect of Microbiome on Non-Alcoholic Fatty Liver Disease and the Role of Probiotics, Prebiotics, and Biogenics. <b>2021</b> , 22,	2
283	Bariatric Surgery and Liver Disease: General Considerations and Role of the Gut-Liver Axis. <b>2021</b> , 13,	3
282	The impact of alteration in gut microbiome in the pathogenesis of nonalcoholic fatty liver disease. <b>2021</b> , 34, 477-482	2
281	Role of microbiota and related metabolites in gastrointestinal tract barrier function in NAFLD. <b>2021</b> , 9, 1879719	0
280	Gut Microbiota Composition of Biliary Atresia Patients Before Kasai Portoenterostomy Associates With Long-term Outcome. <b>2021</b> , 73, 485-490	2
279	Molecular and Pathophysiological Links between Metabolic Disorders and Inflammatory Bowel Diseases. <b>2021</b> , 22,	5
278	Host-Microbiota Interactions in Liver Inflammation and Cancer. <b>2021</b> , 13,	2
277	The Other Side of Malnutrition in Inflammatory Bowel Disease (IBD): Non-Alcoholic Fatty Liver Disease. <b>2021</b> , 13,	1
276	Contribution of gut microbiota to nonalcoholic fatty liver disease: Pathways of mechanisms. <b>2021</b> , 44, 61-68	5
275	The Gut Microbiota-Derived Immune Response in Chronic Liver Disease. <b>2021</b> , 22,	3
274	The Role of Intestinal Permeability in Gastrointestinal Disorders and Current Methods of Evaluation. <b>2021</b> , 8, 717925	9

273	Gut inflammation exacerbates high-fat diet induced steatosis by suppressing VLDL-TG secretion through HNF4 $\beta$ pathway. <b>2021</b> , 172, 459-469	2
272	Hepatic microbiome in healthy lean and obese humans. <b>2021</b> , 3, 100299	3
271	Effect of Lycium barbarum polysaccharide supplementation in non-alcoholic fatty liver disease patients: study protocol for a randomized controlled trial. <b>2021</b> , 22, 566	5
270	Drug-induced Fatty Liver Disease: Pathogenesis and Treatment. <b>2021</b> , 9, 731-737	0
269	Chronic liver disease enables gut Enterococcus faecalis colonization to promote liver carcinogenesis.. <b>2021</b> , 2, 1039-1054	6
268	Novel approaches to intervene gut microbiota in the treatment of chronic liver diseases. <b>2021</b> , 35, e21871	5
267	Gut Microbiome Alteration after Reboxetine Administration in Type-1 Diabetic Rats. <b>2021</b> , 9,	0
266	The Effect of Probiotics (MCP BCMC Strains) on Hepatic Steatosis, Small Intestinal Mucosal Immune Function, and Intestinal Barrier in Patients with Non-Alcoholic Fatty Liver Disease. <b>2021</b> , 13,	8
265	Genetics Is of the Essence to Face NAFLD. <b>2021</b> , 9,	7
264	Positive Effects of Exercise Intervention without Weight Loss and Dietary Changes in NAFLD-Related Clinical Parameters: A Systematic Review and Meta-Analysis. <b>2021</b> , 13,	7
263	Effects of Oral Vitamin C Supplementation on Liver Health and Associated Parameters in Patients With Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial. <b>2021</b> , 8, 745609	2
262	Gut-liver axis-mediated mechanism of liver cancer: A special focus on the role of gut microbiota. <b>2021</b> , 112, 4433-4443	6
261	Role of Barrier Integrity and Dysfunctions in Maintaining the Healthy Gut and Their Health Outcomes. <b>2021</b> , 12, 715611	1
260	Intestine-liver crosstalk in Type 2 Diabetes and non-alcoholic fatty liver disease. <b>2021</b> , 123, 154844	4
259	Nonalcoholic Fatty Liver Disease and the Kidney: A Review. <b>2021</b> , 9,	2
258	Arjunolic acid from Cyclocarya paliurus ameliorates nonalcoholic fatty liver disease in mice via activating Sirt1/AMPK, triggering autophagy and improving gut barrier function. <b>2021</b> , 86, 104686	1
257	Gut microbiota exaggerates triclosan-induced liver injury via gut-liver axis. <b>2022</b> , 421, 126707	6
256	Links between gut microbiome composition and fatty liver disease in a large population sample. <b>2021</b> , 13, 1-22	12

255	Macrophages as a source of fibrosis biomarkers for non-alcoholic fatty liver disease. <b>2021</b> , 44, 175-186	1
254	The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease. <b>2021</b> , 27, 22-43	14
253	The pathophysiology of gut-liver connection. <b>2021</b> , 97-122	
252	Response to Ianiro et al. <b>2021</b> , 116, 1361-1362	
251	Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD). <b>2021</b> , 2310, 201-246	5
250	The interplay between host cellular and gut microbial metabolism in NAFLD development and prevention. <b>2021</b> , 131, 564-582	3
249	Intestinal Barrier in Autism. <b>2014</b> , 2047-2060	2
248	Plasma Oxylipins Levels in Nonalcoholic Fatty Liver Disease. <b>2020</b> , 65, 3605-3613	4
247	Pathogenesis of Nonalcoholic Fatty Liver Disease. <b>2018</b> , 369-390.e14	1
246	Pathophysiological mechanisms underlying MAFLD. <b>2020</b> , 14, 1875-1887	20
245	Processes exacerbating apoptosis in non-alcoholic steatohepatitis. <b>2019</b> , 133, 2245-2264	6
244	Non-alcoholic fatty liver disease: a metabolic burden promoting atherosclerosis. <b>2020</b> , 134, 1775-1799	9
243	Microbiota, NASH, HCC and the potential role of probiotics. <b>2017</b> , 38, 231-240	113
242	Links between gut microbiome composition and fatty liver disease in a large population sample.	2
241	Peroxisomal Oxidation regulates whole body metabolism, inflammatory vigor, and pathogenesis of nonalcoholic fatty liver disease. <b>2018</b> , 3,	35
240	Intestinal activation of Notch signaling induces rapid onset hepatic steatosis and insulin resistance. <b>2011</b> , 6, e20767	9
239	VSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation. <b>2012</b> , 7, e45425	76
238	Effects of Lactobacillus paracasei CNCM I-4034, Bifidobacterium breve CNCM I-4035 and Lactobacillus rhamnosus CNCM I-4036 on hepatic steatosis in Zucker rats. <b>2014</b> , 9, e98401	55

237	Intestinal lesions are associated with altered intestinal microbiome and are more frequent in children and young adults with cystic fibrosis and cirrhosis. <b>2015</b> , 10, e0116967	57
236	Labetalol Prevents Intestinal Dysfunction Induced by Traumatic Brain Injury. <b>2015</b> , 10, e0133215	14
235	The Role of Morbid Obesity in the Promotion of Metabolic Disruptions and Non-Alcoholic Steatohepatitis by Helicobacter Pylori. <b>2016</b> , 11, e0166741	9
234	Fructo-oligosaccharides and intestinal barrier function in a methionine-choline-deficient mouse model of nonalcoholic steatohepatitis. <b>2017</b> , 12, e0175406	38
233	Lubiprostone improves intestinal permeability in humans, a novel therapy for the leaky gut: A prospective randomized pilot study in healthy volunteers. <b>2017</b> , 12, e0175626	24
232	Dysbiosis of the Duodenal Mucosal Microbiota Is Associated With Increased Small Intestinal Permeability in Chronic Liver Disease. <b>2019</b> , 10, e00068	9
231	PERIPHERAL BLOOD ENDOTOXIN LEVELS ARE NOT ASSOCIATED WITH SMALL INTESTINAL BACTERIAL OVERGROWTH IN NONALCOHOLIC FATTY LIVER DISEASE WITHOUT CIRRHOSIS. <b>2020</b> , 57, 471-476	3
230	An assessment of bacterial overgrowth and translocation in the non-alcoholic fatty liver of patients with morbid obesity. <b>2019</b> , 111, 294-300	3
229	Glycine protects against high sucrose and high fat-induced non-alcoholic steatohepatitis in rats. <b>2016</b> , 7, 80223-80237	21
228	Association of mRNA expression of iron metabolism-associated genes and progression of non-alcoholic steatohepatitis in rats. <b>2018</b> , 9, 26183-26194	8
227	Suppression of FoxO6 by lipopolysaccharide in aged rat liver. <b>2015</b> , 6, 34143-57	11
226	Emerging risk factors for nonalcoholic fatty liver disease associated hepatocellular carcinoma. <b>2020</b> , 6,	5
225	Risk of Kidney Dysfunction IN Nafld. <b>2020</b> , 26, 1045-1061	5
224	Identifying Novel Targets for Treatment of Liver Fibrosis: What Can We Learn from Injured Tissues which Heal Without a Scar?. <b>2015</b> , 16, 1332-46	10
223	Non-Alcoholic Fatty Liver Disease, Bile Acids and Intestinal Microbiota. <b>2018</b> , 28, 84-90	3
222	Molecular mechanisms of hepatic fibrosis in chronic liver diseases. <b>2020</b> , 32,	9
221	Microbial Community of Kefir and its Impact on the Gastrointestinal Microbiome in Health and Disease. <b>2020</b> , 74, 58-64	2
220	Role of intestinal microbiota in the formation of non-alcoholic fatty liver disease. <b>2019</b> , 91, 143-148	6

219	The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension. <b>2012</b> , 18, 337-46	84
218	Can Walnut Serve as a Magic Bullet for the Management of Non-Alcoholic Fatty Liver Disease?. <b>2021</b> , 11, 218	2
217	Genetic and metabolic factors: the perfect combination to treat metabolic associated fatty liver disease. <b>2020</b> , 1, 218-243	3
216	Adiponectin, a key adipokine in obesity related liver diseases. <b>2011</b> , 17, 2801-11	170
215	Lipopolysaccharide induces and activates the Nalp3 inflammasome in the liver. <b>2011</b> , 17, 4772-8	97
214	Tumor necrosis factor alpha increases intestinal permeability in mice with fulminant hepatic failure. <b>2012</b> , 18, 5042-50	15
213	Effect of salvianolate on intestinal epithelium tight junction protein zonula occludens protein 1 in cirrhotic rats. <b>2012</b> , 18, 7040-7	8
212	High-fat-induced intestinal permeability dysfunction associated with altered fecal bile acids. <b>2012</b> , 18, 923-9	102
211	Potential role of Helicobacter pylori infection in nonalcoholic fatty liver disease. <b>2013</b> , 19, 7024-31	34
210	Nonalcoholic fatty liver disease is associated with benign gastrointestinal disorders. <b>2013</b> , 19, 8301-11	21
209	Breath volatile organic compounds for the gut-fatty liver axis: promise, peril, and path forward. <b>2014</b> , 20, 9017-25	6
208	Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age?. <b>2014</b> , 20, 9072-89	85
207	Intestinal dendritic cells change in number in fulminant hepatic failure. <b>2015</b> , 21, 4883-93	4
206	Endocrine causes of nonalcoholic fatty liver disease. <b>2015</b> , 21, 11053-76	43
205	Helicobacter pylori infection is not associated with nonalcoholic fatty liver disease. <b>2016</b> , 22, 2592-600	40
204	Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation. <b>2019</b> , 25, 4814-4834	45
203	Intestinal permeability after Mediterranean diet and low-fat diet in non-alcoholic fatty liver disease. <b>2019</b> , 25, 509-520	29
202	Natural products that target macrophages in treating non-alcoholic steatohepatitis. <b>2020</b> , 26, 2155-2165	4

201	Gut microbiota mediated molecular events and therapy in liver diseases. <b>2020</b> , 26, 7603-7618	6
200	Innate immune signaling and gut-liver interactions in non-alcoholic fatty liver disease. <b>2014</b> , 3, 377-85	25
199	The Effect of Symbiotic Supplementation on Liver Enzymes, C-reactive Protein and Ultrasound Findings in Patients with Non-alcoholic Fatty Liver Disease: A Clinical Trial. <b>2016</b> , 7, 59	48
198	Clinical Studies Evaluating Effects of Probiotics on Parameters of Intestinal Barrier Function. <b>2013</b> , 03, 212-221	16
197	CD14 upregulation as a distinct feature of non-alcoholic fatty liver disease after pancreatoduodenectomy. <b>2013</b> , 5, 189-95	8
196	From the stomach to other organs: Helicobacter pylori and the liver. <b>2015</b> , 7, 2136-46	32
195	Clinical relevance of intestinal barrier dysfunction in common gastrointestinal diseases. <b>2020</b> , 11, 114-130	5
194	Starring role of toll-like receptor-4 activation in the gut-liver axis. <b>2015</b> , 6, 99-109	27
193	Resolvin D1 Ameliorates Hepatic Steatosis via Remodeling Gut Microbiota and Restoring Intestinal Barrier Integrity in DSS-Induced Chronic Colitis.	
192	Green Plant Pigment, Chlorophyllin, Ameliorates Non-alcoholic Fatty Liver Diseases (NAFLDs) Through Modulating Gut Microbiome in Mice. <b>2021</b> , 12, 739174	0
191	Effect of Fermented Rice Drink (Amazake) on Patients with Nonalcoholic Fatty Liver Disease and Periodontal Disease: A Pilot Study. <b>2021</b> , 4, 36	1
190	Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC. <b>2021</b> , 9,	1
189	Impacts of Fructose on Intestinal Barrier Function, Inflammation and Microbiota in a Piglet Model. <b>2021</b> , 13,	1
188	Intestinal adaptations to energy source of milk replacer in neonatal dairy calves. <b>2021</b> , 104, 12079-12093	0
187	Hepatologie (II). <b>2010</b> , 547-583	
186	Fatty Liver. <b>2011</b> , 437-447	
185	Metagenomic Applications and the Potential for Understanding Chronic Liver Disease. <b>2011</b> , 277-295	
184	Enteropathic Arthritis. <b>2013</b> , 1251-1268	



183 Diabetes and Liver Disease. **2015**, 1-25

182 Nonalcoholic Fatty Liver Disease. 2056-2069

181 Bacterial Overgrowth. 1294-1304

180 Obesity, Cardiometabolic Risk, and Chronic Kidney Disease. **2016**, 181-198

179 Metabolic Syndrome and the Liver. **2016**, 149-177

178 Diabetes and Liver Disease. **2017**, 705-729

177 Role of Endotoxin and TNF in Developing NAFLD in Non-Obese Egyptian Patients. **2017**, 05, 7-15

176 Immunopathology of the Hepatobiliary System. **2017**, 329-417

175 Diabetes and Liver Disease. **2017**, 1-26

174 Metabolik Sendrom Tedavisinde Bařsak Mikrobiyotasının Probiyotikler ve Ėelinde Saccharomyces Boulardii ile Modlasyonu.

173 High prevalence of non-alcoholic fatty liver disease in patients with inflammatory bowel disease receiving anti-tumor necrosis factor therapy. **2019**, 32, 463-468 8

172 Genetic Aspects of Non-Alcoholic Fatty Liver Disease. **2019**, 17, 442-448 1

171 Fructo-Oligosaccharides Ameliorate Steatohepatitis, Visceral Adiposity, and Associated Chronic Inflammation via Increased Production of Short-Chain Fatty Acids in a Mouse Model of Non-alcoholic Steatohepatitis.

170 Ammonia level of capillary blood in patients with inflammatory bowel diseases and nonalcoholic fatty liver disease. **2020**, 49-51

169 Safety of TNF inhibitors in rheumatic disease in case of NAFLD and cirrhosis. **2020**, 50, 544-548 2

168 Endotoxins and Non-Alcoholic Fatty Liver Disease. **2021**, 12, 770986 9

167 Celiac Disease and Elevated Liver Enzymes: A Review. **2021**, 9, 116-124 3

166 Fructo-Oligosaccharides Ameliorate Steatohepatitis, Visceral Adiposity, and Associated Chronic Inflammation via Increased Production of Short-Chain Fatty Acids in a Mouse Model of Non-alcoholic Steatohepatitis.

165	Etiopathogenesis of NAFLD: Diet, Gut, and NASH. <b>2020</b> , 73-95	
164	The Gut Microbiome and Liver Disease. <b>2020</b> , 1062-1068	0
163	Dysbiosis of gut microbiota and human diseases. <b>2020</b> , 25, 66	0
162	Comparative analysis of the composition of intestinal microbiome in patients with liver diseases. <b>2020</b> , 15-22	
161	Rifaximin-Alpha and Other Crystalline Forms of Rifaximin: Are There Any Differences?. <b>2020</b> , 65, 52-62	1
160	Non-alcoholic fatty liver disease, diet and gut microbiota. <b>2014</b> , 13, 461-90	14
159	Intestinal mucosal barrier dysfunction participates in the progress of nonalcoholic fatty liver disease. <b>2015</b> , 8, 3648-58	26
158	Abnormal intestinal permeability and microbiota in patients with autoimmune hepatitis. <b>2015</b> , 8, 5153-60	60
157	Protective effect of salvianolic acid B on NASH rat liver through restoring intestinal mucosal barrier function. <b>2015</b> , 8, 5203-9	12
156	A systems biology analysis protein-protein interaction of NASH and IBD based on comprehensive gene information. <b>2017</b> , 10, 194-201	23
155	Clinicopathological and immunological characteristics and outcome of concomitant coeliac disease and non-alcoholic fatty liver disease in adults: a large prospective longitudinal study. <b>2018</b> , 5, e000150	5
154	Influence of colonic dialysis using Chinese medicine on creatinine decomposition by intestinal bacteria in uremia rats. <b>2019</b> , 11, 6577-6584	1
153	Nonalcoholic fatty liver disease is associated with worse intestinal complications in patients hospitalized for infection.. <b>2021</b> , 13, 1777-1790	1
152	Effects of larazotide acetate, a tight junction regulator, on the liver and intestinal damage in acute liver failure in rats. <b>2021</b> , 40, S693-S701	2
151	The Effect of Pathogen-Associated Molecular Patterns on Peripheral Blood Monocytes in Patients with Fatty Liver Disease. <b>2021</b> ,	0
150	Disease activity in inflammatory bowel disease patients is associated with increased liver fat content and liver fibrosis during follow-up. <b>2021</b> , 1	
149	Non-alcoholic fatty liver disease (NAFLD): a multi-system disease influenced by ageing and sex, and affected by adipose tissue and intestinal function.. 1-34	0
148	Gut microbiota and immune system in liver cancer: Promising therapeutic implication from development to treatment. <b>2021</b> , 13, 1616-1631	2

147	Overview of the microbiota in the gut-liver axis in viral B and C hepatitis. <b>2021</b> , 27, 7446-7461		1
146	Effects of probiotics on the improvement and regulation of intestinal barrier dysfunction and immune imbalance in intra-abdominal infections (Review). <b>2021</b> , 2,		1
145	Liver involvement in inflammatory bowel disease: What should the clinician know?. <b>2021</b> , 13, 1534-1551		0
144	A GLP-1/GLP-2 receptor dual agonist to treat non-alcoholic steatohepatitis: targeting the gut-liver axis and microbiome. <i>Hepatology</i> , <b>2021</b> ,	11.2	1
143	GP73 is a TBC-domain Rab GTPase-activating protein contributing to the pathogenesis of non-alcoholic fatty liver disease without obesity. <b>2021</b> , 12, 7004		1
142	Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD). <b>2021</b> , 12, 100149		5
141	Zölkäe/Einheimische Sprue. <b>2015</b> , 1-25		
140	Zölkäe/Einheimische Sprue. <b>2016</b> , 1-25		
139	Apigenin Alleviates Obesity-Associated Metabolic Syndrome by Regulating the Composition of the Gut Microbiome.. <b>2021</b> , 12, 805827		5
138	Insulin resistance per se drives early and reversible dysbiosis-mediated gut barrier impairment and bactericidal dysfunction.. <b>2022</b> , 57, 101438		1
137	Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice.. <b>2022</b> , 12, 484		
136	Resolvin D1 ameliorates hepatic steatosis by remodeling the gut microbiota and restoring the intestinal barrier integrity in DSS-induced chronic colitis.. <b>2021</b> , 103, 108500		0
135	GUT MICROBIOTA IN THE PATHOLOGY AND PREVENTION OF LIVER DISEASE. <b>2021</b> , 3, 81		
134	A Potential Role for Bile Acid Signaling in Celiac Disease-Associated Fatty Liver.. <b>2022</b> , 12,		1
133	Demonstration of gut-barrier dysfunction in early stages of non-alcoholic fatty liver disease: A proof-of-concept study. <b>2022</b> ,		0
132	The Intestinal Barrier and Its Dysfunction in Patients with Metabolic Diseases and Non-Alcoholic Fatty Liver Disease.. <b>2022</b> , 23,		1
131	Lentianin Supplementation Protects the Gut-Liver Axis and Prevents Steatohepatitis: The Role of Gut Microbiota Involved.. <b>2021</b> , 8, 803691		2
130	Alterations of nitric oxide homeostasis as trigger of intestinal barrier dysfunction in non-alcoholic fatty liver disease.. <b>2022</b> ,		3

129	Exploring the role of gut microbiome in male reproduction.. <b>2021,</b>	4
128	Metabolic Risks Are Increasing in Non-B Non-C Early-Stage Hepatocellular Carcinoma: A 10-Year Follow-Up Study.. <b>2022, 12, 816472</b>	1
127	Oxidative Stress in Non-Alcoholic Fatty Liver Disease. <b>2022, 2, 30-76</b>	1
126	The Gut-Liver Axis in Nonalcoholic Fatty Liver Disease: Association of Intestinal Permeability with Disease Severity and Treatment Outcomes. <b>2022, 2022, 1-7</b>	0
125	Circadian Rhythms, the Gut Microbiome, and Metabolic Disorders. <b>2022, 1, 93-105</b>	2
124	The potential of soluble CD14 in discriminating nonalcoholic steatohepatitis from nonalcoholic fatty liver disease.. <b>2022,</b>	
123	Implication des bactéries orales et intestinales dans le déroulé des maladies cardio-métaboliques et du diabète de type 2. <b>2022,</b>	0
122	Intestinal Barrier and Permeability in Health, Obesity and NAFLD.. <b>2021, 10,</b>	9
121	Heat-Inactivated Improves Gut Permeability but Does Not Prevent Development of Non-Alcoholic Steatohepatitis in Diet-Induced Obese Ldlr <sup>-/-</sup> Leiden Mice.. <b>2022, 23,</b>	1
120	Alleviation of Hepatic Steatosis: Dithizone-Related Gut Microbiome Restoration During Paneth Cell Dysfunction.. <b>2022, 13, 813783</b>	0
119	Individuals with Metabolic Syndrome show altered fecal lipidomic profiles with no signs of intestinal inflammation or increased intestinal permeability: a pilot study.	
118	The Role of Gut-Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC.. <b>2022, 10,</b>	7
117	Molecular Mechanism Underlying the Regulatory Effect of Vine Tea on Metabolic Syndrome by Targeting Redox Balance and Gut Microbiota.. <b>2022, 9, 802015</b>	0
116	The effect of daily consumption of probiotic yogurt on liver enzymes, steatosis and fibrosis in patients with nonalcoholic fatty liver disease (NAFLD): study protocol for a randomized clinical trial.. <b>2022, 22, 102</b>	1
115	NAFLD and the Gut-Liver Axis: Exploring an Undernutrition Perspective.. <b>2022,</b>	3
114	Electroacupuncture Ameliorates Intestinal Barrier Destruction in Mice With Bile Duct Ligation-Induced Liver Injury by Activating the Cholinergic Anti-Inflammatory Pathway.. <b>2022,</b>	
113	Gut Microbiota Targeted Approach in the Management of Chronic Liver Diseases.. <b>2022, 12, 774335</b>	2
112	Effect of Jiangan-Jiangzhi Pill on Gut Microbiota and Chronic Inflammatory Response in Rats with Non-alcoholic Fatty Liver.. <b>2022,</b>	0

111	Inflammatory Bowel Disease-associated Fatty Liver Disease: the Potential Effect of Biologic Agents.. <b>2021,</b>	1
110	Non-alcoholic fatty liver disease in irritable bowel syndrome: More than a coincidence?. <b>2021, 13, 1816-1827</b>	1
109	Eradication of small intestinal bacterial overgrowth in irritable bowel syndrome using herbal therapy: A case report. <b>2021, 2,</b>	
108	NAFLD Associated Comorbidity. <b>2021, 5-13</b>	
107	Gut Homeostasis; Microbial Cross Talks in Health and Disease Management. <b>2021, 9, 1017-1045</b>	
106	Molecular Immune Mechanism of Intestinal Microbiota and Their Metabolites in the Occurrence and Development of Liver Cancer.. <b>2021, 9, 702414</b>	1
105	Metabolic Associated Fatty Liver Disease in Children-From Atomistic to Holistic.. <b>2021, 9,</b>	1
104	Antibiotics and Liver Cirrhosis: What the Physicians Need to Know.. <b>2021, 11,</b>	4
103	Inflammation and Fibrogenesis in MAFLD: Role of the Hepatic Immune System.. <b>2021, 8, 781567</b>	0
102	Association of small intestinal bacterial overgrowth with nonalcoholic fatty liver disease in children: A meta-analysis. <b>2021, 16, e0260479</b>	2
101	Acid-treated high-amylose corn starch suppresses high-fat diet-induced steatosis.. <b>2022,</b>	0
100	Table_1.docx. <b>2020,</b>	
99	Table_2.pdf. <b>2020,</b>	
98	Image_1.tif. <b>2020,</b>	
97	Table_1.docx. <b>2020,</b>	
96	Table_1.docx. <b>2020,</b>	
95	Data_Sheet_1.pdf. <b>2019,</b>	
94	FEATURES OF INTESTINAL MICROBIOTA IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE: EFFECTS ON MARKERS OF INFLAMMATION AND HEPATIC STEATOSIS. <b>2022, 75, 611-618</b>	0

93	Receptor-interacting protein kinase-1 ablation in liver parenchymal cells promotes liver fibrosis in murine NASH without affecting other symptoms.. <b>2022</b> , 1	0
92	Epithelial protective therapy in comorbid diseases. Practical Guidelines for Physicians.	0
91	Impact of Helicobacter pylori Eradication on the Risk of Incident Nonalcoholic Fatty Liver Disease: A Cohort Study.	1
90	Individuals with Metabolic Syndrome Show Altered Fecal Lipidomic Profiles with No Signs of Intestinal Inflammation or Increased Intestinal Permeability. <b>2022</b> , 12, 431	
89	Glucocorticosteroids and the Risk of NAFLD in Inflammatory Bowel Disease. <b>2022</b> , 2022, 1-13	2
88	Pathogenetic and clinical significance of the gut-liver microbiota axis. <b>2022</b> , 69-75	
87	The Apparent Asymmetrical Relationship Between Small Bowel Bacterial Overgrowth, Endotoxemia, and Liver Steatosis and Fibrosis in Cirrhotic and Non-Cirrhotic Patients: A Single-Center Pilot Study.. <b>2022</b> , 9, 872428	1
86	Role of gut dysbiosis in chronic liver disease leading to fibrosis. <b>2022</b> , 103-125	
85	A Nine-Strain Bacterial Consortium Improves Portal Hypertension and Insulin Signaling and Delays NAFLD Progression In Vivo. <b>2022</b> , 10, 1191	1
84	Efficacy of a Novel Therapeutic, Based on Natural Ingredients and Probiotics, in a Murine Model of Multiple Food Intolerance and Maldigestion. <b>2022</b> , 14, 2251	0
83	Association of serum and fecal bile acid patterns with liver fibrosis in biopsy-proven nonalcoholic fatty liver disease: An observational study. <b>2022</b> , Publish Ahead of Print,	0
82	Mechanisms behind the Role of SIBO in Non-Alcoholic Fatty Liver Disease: An Interplay between Liver, Gut Microbiota and Nutrition. <b>2022</b> , 18,	
81	Intestinal Barrier Dysfunction in Fatty Liver Disease: Roles of Microbiota, Mucosal Immune System, and Bile Acids. <b>2022</b> , 42, 122-137	0
80	Poria cocos polysaccharides rescue pyroptosis-driven gut vascular barrier disruption in orderv to alleviates non-alcoholic steatohepatitis. <b>2022</b> , 115457	0
79	Links between Celiac Disease and Small Intestinal Bacterial Overgrowth: A Systematic Review and Meta-Analysis.	0
78	Effects of Dietary Nutrients on Fatty Liver Disease Associated With Metabolic Dysfunction (MAFLD): Based on the Intestinal-Hepatic Axis. 9,	1
77	Fufang Zhenzhu Tiaozhi Capsule Prevents Intestinal Inflammation and Barrier Disruption in Mice With Non-Alcoholic Steatohepatitis. 13,	
76	Is Non-Alcoholic Fatty Liver Disease Connected with Cognition? The Complex Interplay between Liver and Brain. <b>2022</b> , 3, 355-363	1

75	Novel insights into non-alcoholic fatty liver disease and dementia: insulin resistance, hyperammonemia, gut dysbiosis, vascular impairment, and inflammation. <b>2022</b> , 12,	2
74	Hepatoprotective effect of curcumin against bisphenol A-induced hepatic steatosis via modulating gut microbiota dysbiosis and related gut-liver axis activation in CD-1 mice. <b>2022</b> , 109103	0
73	The Role of Insulin Resistance in Fueling NAFLD Pathogenesis: From Molecular Mechanisms to Clinical Implications. <b>2022</b> , 11, 3649	1
72	Amelioration of Non-Alcoholic Steatohepatitis by Atractylodes macrocephala Polysaccharide, Chlorogenic Acid, and Geniposide Combination Is Associated With Reducing Endotoxin Gut Leakage. 12,	0
71	The Pathogenesis of HCC Driven by NASH and the Preventive and Therapeutic Effects of Natural Products. 13,	1
70	Intestinal aberrant sphingolipid metabolism shaped-gut microbiome and bile acids metabolome in the development of hepatic steatosis. <b>2022</b> , 36,	0
69	Effects of Probiotic Supplementation during Pregnancy on the Future Maternal Risk of Metabolic Syndrome. <b>2022</b> , 23, 8253	1
68	Dietary fat composition shapes bile acid metabolism and severity of liver injury in a pig model of pediatric NAFLD.	1
67	Shared mechanisms between cardiovascular disease and NAFLD.	1
66	PERIODONTAL TREATMENT AND USUAL CARE FOR NON-ALCOHOLIC FATTY LIVER DISEASE: A MULTICENTER, RANDOMIZED CONTROLLED TRIAL. <b>2022</b> , Publish Ahead of Print,	1
65	Effect of Calcium-Sulphate-Bicarbonate Water in a Murine Model of Non-Alcoholic Fatty Liver Disease: A Histopathology Study. <b>2022</b> , 23, 10065	0
64	Gut microbiome in non-alcoholic fatty liver disease. <b>2022</b> , 132, 11-15	0
63	Phytic Acid Improves Hepatic Steatosis, Inflammation, and Oxidative Stress in High-Fat Diet (HFD)-Fed Mice by Modulating the Gut-Liver Axis. <b>2022</b> , 70, 11401-11411	0
62	Targeting the Gut Microbiome to Treat Metabolic Dysfunction-Associated Fatty Liver Disease: Ready for Prime Time?. <b>2022</b> , 11, 2718	2
61	Therapies for non-alcoholic fatty liver disease: A 2022 update. 14, 1718-1729	0
60	Risk of dementia or cognitive impairment in non-alcoholic fatty liver disease: A systematic review and meta-analysis. 14,	0
59	Gut microbiome and microbial metabolites in NAFLD and after bariatric surgery: Correlation and causality. 13,	0
58	The development of the Metabolic-associated Fatty Liver Disease during pharmacotherapy of mental disorders - a review. <b>2022</b> ,	0

57	Structural and functional features of the colon in patients with non-alcoholic fatty liver disease and comorbid pathology. <b>2022</b> , 37-42	0
56	Topic: Nutrition and the Gut-Liver-Brain Axis.	0
55	Current Research on the Pathogenesis of NAFLD/NASH and the Gut-Liver Axis: Gut Microbiota, Dysbiosis, and Leaky-Gut Syndrome. <b>2022</b> , 23, 11689	2
54	Effect of altered human exposome on the skin and mucosal epithelial barrier integrity.	0
53	Roles of hepatic stellate cells in NAFLD: From the perspective of inflammation and fibrosis. 13,	1
52	The immune response as a therapeutic target in non-alcoholic fatty liver disease. 13,	0
51	Gut-liver axis: Pathophysiological concepts and clinical implications. <b>2022</b> , 34, 1700-1718	4
50	Effects of garlic supplementation on non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials. <b>2022</b> , 99, 105294	0
49	Gut-Liver Axis and Non-Alcoholic Fatty Liver Disease: A Vicious Circle of Dysfunctions Orchestrated by the Gut Microbiome. <b>2022</b> , 11, 1622	0
48	Investigating dysbiosis and microbial treatment strategies in inflammatory bowel disease based on two modified Koch's postulates. 9,	1
47	Tetragonia hemsleyana leaf extracts ameliorate NAFLD in mice with low-grade colitis via the gut-liver axis.	0
46	The gut-mediated function of polyphenols: Opinions on functional food development for nonalcoholic fatty liver disease. <b>2023</b> , 49, 100972	0
45	Skeletal muscle insulin resistance and adipose tissue hypertrophy persist beyond the reshaping of gut microbiota in young rats fed a fructose-rich diet. <b>2023</b> , 113, 109247	0
44	Elevated serum levels of diamine oxidase, D-lactate and lipopolysaccharides are associated with metabolic-associated fatty liver disease. <b>2023</b> , 35, 94-101	0
43	Clinical and Molecular Insights into Gastrointestinal Dysfunction in Myotonic Dystrophy Types 1 & 2. <b>2022</b> , 23, 14779	0
42	Gut microbiome determines therapeutic effects of OCA on NAFLD by modulating bile acid metabolism.	0
41	The Prevalence of Small Intestinal Bacterial Overgrowth in Patients with Non-Alcoholic Liver Diseases: NAFLD, NASH, Fibrosis, Cirrhosis: A Systematic Review, Meta-Analysis and Meta-Regression. <b>2022</b> , 14, 5261	1
40	Distribution of endotoxin in maternal and fetal body with intrahepatic cholestasis of pregnancy and its association with adverse fetal outcome. <b>2022</b> , 22,	0



- 39 Prognostication in NAFLD: physiological bases, clinical indicators, and newer biomarkers. 0
- 38 Oral microbiota and Liver Diseases. **2023**, 0
- 37 MAFLD and Celiac Disease in Children. **2023**, 24, 1764 0
- 36 Leaky Gut and the Ingredients That Help Treat It: A Review. **2023**, 28, 619 3
- 35 Association between Small Intestinal Bacterial Overgrowth and Subclinical Atheromatous Plaques. **2023**, 12, 314 0
- 34 Hígado graso (parte 1): aspectos generales, epidemiología, fisiopatología e historia natural. **2022**, 37, 420-433 0
- 33 The Impact of Nonalcoholic Fatty Liver Disease on Severe Community-Acquired Pneumonia Outcomes. **2023**, 13, 36 0
- 32 Show Me What You Have Inside—The Complex Interplay between SIBO and Multiple Medical Conditions—A Systematic Review. **2023**, 15, 90 1
- 31 Multifactorial Diseases of the Heart, Kidneys, Lungs, and Liver and Incident Cancer: Epidemiology and Shared Mechanisms. **2023**, 15, 729 0
- 30 Colonic permeability is increased in non-cirrhotic patients with nonalcoholic fatty liver disease. **2023**, 0
- 29 Effect of intestinal microbiota on liver disease and its related future prospection: From the perspective of intestinal barrier damage and microbial metabolites. 0
- 28 Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: pathophysiology and implications for cardiovascular disease. **2023**, 137-173 0
- 27 Gut microbiome as a therapeutic target for liver diseases. **2023**, 322, 121685 0
- 26 The role of small intestinal bacterial overgrowth in obesity and its related diseases. **2023**, 212, 115546 0
- 25 Restoring polyamine levels by supplementation of spermidine modulates hepatic immune landscape in murine model of NASH. **2023**, 1869, 166697 0
- 24 Research progress regarding the effect and mechanism of dietary phenolic acids for improving nonalcoholic fatty liver disease via gut microbiota. **2023**, 22, 1128-1147 1
- 23 Sulforaphane Ameliorates Nonalcoholic Fatty Liver Disease Induced by High-Fat and High-Fructose Diet via LPS/TLR4 in the Gut-Liver Axis. **2023**, 15, 743 0
- 22 Periodontal treatment and microbiome-targeted therapy in management of periodontitis-related nonalcoholic fatty liver disease with oral and gut dysbiosis. 29, 967-996 0

21	Regulatory Effects and Molecular Mechanisms of Tea and Its Active Compounds on Nonalcoholic Fatty Liver Disease.	0
20	Impact of Vancomycin Treatment and Gut Microbiota on Bile Acid Metabolism and the Development of Non-Alcoholic Steatohepatitis in Mice. <b>2023</b> , 24, 4050	0
19	The Effects of Probiotics on Small Intestinal Microbiota Composition, Inflammatory Cytokines and Intestinal Permeability in Patients with Non-Alcoholic Fatty Liver Disease. <b>2023</b> , 11, 640	1
18	Translational characterization of the temporal dynamics of metabolic dysfunctions in liver, adipose tissue and the gut during diet-induced NASH development in Ldlr <sup>-/-</sup> Leiden mice. <b>2023</b> , 9, e13985	0
17	Gut-Microbiota Dysbiosis in Stroke-Prone Spontaneously Hypertensive Rats with Diet-Induced Steatohepatitis. <b>2023</b> , 24, 4603	0
16	Yogurt starter strains ameliorate intestinal barrier dysfunction via activating AMPK in Caco-2 cells.	0
15	Role of immune responses for development of NAFLD-associated liver cancer and prospects for therapeutic modulation. <b>2023</b> ,	0
14	Small Intestinal Bacterial Overgrowth and Non-Alcoholic Fatty Liver Disease: What Do We Know in 2023?. <b>2023</b> , 15, 1323	0
13	Global publication trends and research hotspots of the gut-liver axis in NAFLD: A bibliometric analysis. 14,	0
12	Prevalence of Small Intestinal Bacterial Overgrowth Syndrome in Patients with Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis: A Cross-Sectional Study. <b>2023</b> , 11, 723	0
11	Microbiome-liver crosstalk: A multihit therapeutic target for liver disease. 29, 1651-1668	0
10	Pattern recognition receptors in the development of nonalcoholic fatty liver disease and progression to hepatocellular carcinoma: An emerging therapeutic strategy. 14,	0
9	Proteomic Analysis Reveals Changes in Tight Junctions in the Small Intestinal Epithelium of Mice Fed a High-Fat Diet. <b>2023</b> , 15, 1473	0
8	Impact of Sex and Gender on Clinical Management of Patients with Advanced Chronic Liver Disease and Type 2 Diabetes. <b>2023</b> , 13, 558	1
7	Glutathione: Pharmacological aspects and implications for clinical use in non-alcoholic fatty liver disease. 10,	0
6	Faecal Microbiota Transplantation, Paving the Way to Treat Non-Alcoholic Fatty Liver Disease. <b>2023</b> , 24, 6123	0
5	Gut metabolomics and 16S rRNA sequencing analysis of the effects of arecoline on non-alcoholic fatty liver disease in rats. 14,	0
4	Short chain fatty acids: key regulators of the local and systemic immune response in inflammatory diseases and infections. <b>2023</b> , 13,	0

- 3 Mediterranean Diet Improves Plasma Biomarkers Related to Oxidative Stress and Inflammatory Process in Patients with Non-Alcoholic Fatty Liver Disease. **2023**, 12, 833 ○
- 2 The Effect of Bioactive Aliment Compounds and Micronutrients on Non-Alcoholic Fatty Liver Disease. **2023**, 12, 903 ○
- 1 Milk-derived extracellular vesicles protect intestinal barrier integrity in the gut-liver axis. **2023**, 9, ○